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Though the GluK4 kainate receptor subunit shows limited homology and a
restricted expression pattern relative to other kainate receptor subunits, its
ablation results in distinct behavioral and molecular phenotypes.

To study the function of GluK4, I generated a global GluK4 knockout mouse line
by crossing a germline-expressed cre transgenic mouse line with a GluK4-floxed
mouse line in which exon 16 of GRIK4, the gene encoding GluK4, was flanked by
lox-P sites (floxed). Thorough characterization of GluK4 expression in the
resulting knockout mice using RT-PCR and a custom-designed anti-GluK4
antibody revealed that GRIK4 mRNA expression persisted though GluK4 protein
expression was ablated.

In keeping with genome-wide studies in humans that have implicated GluK4 in
bipolar disorder and schizophrenia, I found that GluK4 mice displayed reduced
anxiety, increased risk-taking behavior, reduced depressive behavior, impaired
sensorimotor gating, and hyperlocomotion relative to wild-type mice. GluK4
knockout mice also demonstrated impaired fear memory and spatial memory.

Furthermore, my findings indicate that GluK4 is a key mediator of excitotoxic
neurodegeneration: GluK4 knockout mice showed robust neuroprotection in the
Cornu Ammonis 3 (CA3) region of the hippocampus following intrahippocampal
injection of kainate, a potent excitotoxin, and widespread neuroprotection
throughout the hippocampus following hypoxia-ischemia. Molecular and
biochemical analysis of kainate- and sham-treated wild-type and GluK4 knockout
hippocampal tissue revealed that GluK4 may act through the c-Jun N-terminal
Kinase (JNK) pathway to regulate the molecular cascades that lead to
excitotoxicity. Finally, I found preliminary evidence to suggest that GluK4 may
regulate hippocampal seizure activity following intraperitoneal injection of
kainate.

Together, these findings suggest that GluK4 may be relevant to the
understanding and treatment of human neuropsychiatric and neurodegenerative
disorders.

To my family.
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CHAPTER 1: INTRODUCTION
Glutamate is the principal excitatory neurotransmitter in the central nervous
system (CNS), and imbalances in glutamatergic transmission have profound
behavioral and physiological consequences. Hypoactivity of the glutamate
system has been implicated in human affective disorders such as schizophrenia,
based initially on clinical observations that glutamate antagonists can mimic
certain symptoms of the disease (Krystal et al., 1994). Conversely, hyperactivity
of the glutamate system can result in excitotoxic neurodegeneration, a form of
neuronal cell death that often accompanies ischemic stroke (Lucas and
Newhouse, 1957; Olney, 1969).

Glutamate Receptor Physiology
Both normal and pathological aspects of excitatory neurotransmission are
contingent upon the interactions between glutamate and its receptors. Glutamate
receptors can be broadly classified as metabotropic or ionotropic. Metabotropic
receptors are G-protein-coupled, and ligand binding results in the activation of
downstream signaling pathways. Ionotropic receptors are ligand-gated ion
channels. Three subtypes of ionotropic receptors – N-methyl-D-aspartate
(NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and
kainate receptors – were initially distinguished by the eponymous glutamate
analogs for which they show the highest affinity (Lodge, 2009). Though kainate
receptors were the last of the three subtypes to be identified (Bettler et al., 1990),
pharmacological isolation of kainate receptor activity from that of NMDA and
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AMPA receptors in vitro, coupled with the genetic ablation of kainate receptor
subunits in vivo, have indicated that they play an essential role in regulating the
overall excitability of neuronal networks.

Like AMPA and NMDA receptors, kainate receptors are permeable to sodium,
potassium, and calcium, though permeability to the latter varies with kainate
receptor subunit mRNA editing (Köhler et al., 1993). Nevertheless, kainate
receptors display a distinct electrophysiological profile upon activation: they
mediate excitatory post-synaptic currents (EPSCs) of smaller amplitude than
AMPA or NMDA receptors, with slow decay kinetics (Castillo et al., 1997; Vignes
and Collingridge, 1997). In response to repetitive stimulation, these postsynaptic
kainate receptors contribute to temporal summation of synaptic input, where
EPSC amplitude increases progressively after each stimulus and neuronal
excitability is enhanced (Frerking and Ohliger-Frerking, 2002). Kainate receptors
are also located pre-synaptically, where they act as autoreceptors. At
glutamatergic synapses, presynaptic kainate receptors modulate excitatory
transmission by facilitating or depressing glutamate release. At γ-Aminobutyric
Acid (GABA)-ergic synapses, presynaptic kainate receptors modulate inhibitory
transmission by facilitating or depressing the release of the inhibitor
neurotransmitter GABA (Rodriguez-Moreno et al., 1997; Schmitz et al., 2000;
Cossart et al., 2001). Furthermore, there is a growing body of evidence to
suggest that kainate receptors can act in a non-canonical, metabotropic fashion.
For instance, kainate receptors can control the excitability of hippocampal
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pyramidal cells by inhibiting slow afterhyperpolarization (sAHP) (Melyan et al.,
2002), a post-synaptic, Ca2+-dependent K+ current that occurs after burst firing to
limit further action potentials. The inhibition of sAHP by kainate receptors is
independent of ionotropic action, and acts through a metabotropic signaling
cascade (Melyan et al., 2002; Melyan and Lancaster, 2004). Thus, through their
many, disparate functions, kainate receptors serve to fine-tune network
excitability, synaptic plasticity, and, potentially, cognition.

Kainate Receptor Subunits
The function of kainate receptors is further specified by their subunit composition.
The five kainate receptor subunit types – GluK1-5 – assemble as tetramers and
share the same general secondary structure: an extracellular N-terminal domain;
a transmembrane domain (M1); a p-loop (M2) domain that begins on the
cytoplasmic face of the cell membrane and penetrates the membrane without
traversing it, then re-emerges on the cytoplasmic face; a second and third
transmembrane domain (M3 and M4); and, finally, the cytoplasmic C-terminal
domain (Oswald et al., 2007) (Figure 1.1). The ligand-binding domain is
comprised of the domain (S1) that falls between the N-terminal domain and the
M1 domain, and the loop (S2) between M3 and M4 (Hollmann et al., 1994; Wo
and Oswald, 1994). The N-terminal domain regulates subunit assembly
(Leuschner and Hoch, 1999), the p-loop forms the receptor pore (Hughes, 1994),
and the C-terminal domain contains cis-acting regulatory elements that can
promote forward trafficking in the case of GluK2 and GluK3 (Yan et al., 2004), or
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endoplasmic reticulum retention in the case of GluK1 and GluK5 (Ren et al.,
2003; Nasu-Nishimura et al., 2006). Depending on the subunit type, the Cterminal domain can interact with several subsets of auxiliary proteins to regulate
receptor trafficking, to stabilize receptors at the synapse, or to modify channel
gating (Coussen and Mulle, 2006).

Despite the similarities in their secondary structures, kainate receptor subunits
differ in their agonist affinities: GluK1-3 have low-affinity agonist binding sites (Kd
in the micromolar range), while GluK4 and GluK5 have high-affinity sites (Kd in
the nanomolar range) (London and Coyle, 1979; Hampson et al., 1987).
Furthermore, GluK4 and GluK5 share 68% sequence homology with each other,
but only 45% with GluK1-3 (Werner et al., 1991; Herb et al., 1992; Sakimura et
al., 1992). Low-affinity subunits can co-assemble to form functional homologous
receptors, while high-affinity subunits must assemble with low-affinity subunits,
as this conformation sterically hinders the endoplasmic reticulum retention motif
that prevents high-affinity subunits from reaching the cell surface on their own
(Herb et al., 1992; Sakimura et al., 1992).
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FIGURE 1.1. General kainate receptor subunit structure. Kainate receptor
subunits have three transmembrane domains, M1, M2, and M3. Interspersed
between M1 and M3 is the pore-forming p-loop domain, M2. S1 and S2 form the
ligand-binding domain. The N-terminal regulates subunit assembly, and the Cterminal mediates receptor trafficking.
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The GluK4 Kainate Receptor Subunit
Unlike the other high-affinity subunit, GluK5, which is expressed throughout the
CNS (Herb et al., 1992), GluK4 mRNA and protein expression are largely
restricted to the CA3 region of the hippocampus (Werner et al., 1991; Darstein et
al., 2003) (Figure 1.2a). Within the CA3, GluK4 mRNA is localized to the
pyramidal cell layer, while GluK4 protein is localized to the stratum lucidum
(Werner et al., 1991; Darstein et al., 2003). The stratum lucidum is comprised of
the axons arising from granule cells in the dentate gyrus (DG) region of the
hippocampus, and their synapses onto CA3 pyramidal cell dendrites (Amaral and
Witter, 1989). The association between DG granule cells and CA3 pyramidal
cells is known as the mossy fiber pathway (Amaral and Witter, 1989) (Figure
1.2b). CA3 pyramidal cells then project to the Cornu Ammonis 1 (CA1) region of
the hippocampus via Schaffer collaterals, or form recurrent collaterals within the
stratum oriens of the CA3 (Amaral and Witter, 1989) (Figure 1.2b). Pyramidal
cells within the CA3 also receive input from the entorhinal cortex (EC) through
the perforant path (Lopes da Silva and Arnolds, 1978).

Outside of the CA3, GluK4 protein also shows limited expression within the
polymorphic layer (hilus) of the DG region of the hippocampus, the pyramidal
layer of the CA1 region of the hippocampus, Purkinje cells in the cerebellum,
scattered neurons in layers II and V of the cortex, and the central terminals of
dorsal root ganglion (DRG) neurons in the spinal dorsal horn (Fogarty et al.,
2000; Darstein et al., 2003; Lucifora et al., 2006) (Figure 1.2a).
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Within the hippocampus, GluK4 co-precipitates with GluK2, but not GluK3, and is
expressed both pre- and post-synaptically (Darstein et al., 2003).
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FIGURE 1.2. Hippocampal subregions and connectivity. (A) The
hippocampus is comprised of 4 major subregions: Cornu Ammonis 1 (CA1; blue),
Cornu Ammonis 2 (CA2; light gray), Cornu Ammonis 3 (CA3; green), and dentate
gyrus (DG; yellow). Pyramidal cells form the stratum pyramidal (SP) of the CA1,
CA2, and CA3 subregions. Dentate granule cells form the stratum granulosum
(SG) of the dentate gyrus. The stratum oriens (SO), stratum lucidum (SL), and
stratum radiatum (SR) are indicated for the CA3, and contain various fibers of
passage. (B) Mossy fibers originating from the SG synapse onto pyramidal cell
fibers in the SL to form the mossy fiber pathway. Pyramidal cells within the CA3
can form recurrent connections. Projections from the CA3 to the CA1 form the
Schaffer collaterals.
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The restricted expression pattern of GluK4 suggests that receptors containing
this subunit may have distinct signaling properties and physiological functions.
Initial electrophysiological studies using GluK4 knockout mice have revealed that
GluK4 ablation results in both pre- and post-synaptic deficits. The mossy fiber
presynaptic fiber volley induced by kainate, a strong kainate receptor agonist, is
reduced in GluK4 knockout mice relative to wild-type mice (Catches et al., 2012).
GluK4 knockout mice also display decreased EPSC amplitude (Fernandes et al.,
2009) and impaired mossy fiber long-term potentiation (LTP) (Catches et al.,
2012). Meanwhile, mossy fiber LTP is decreased in GluK4/GluK5 doubleknockout mice (Fernandes et al., 2009), but unaffected in GluK5 knockout mice
(Contractor et al., 2003), indicating that GluK4 plays a key role in LTP.

GluK4 in Learning and Memory
LTP, a form of synaptic plasticity, occurs when synaptic transmission is
enhanced between a pre- and post-synaptic cell (Bliss and Collingridge, 1993).
According to classical Hebbian theory, this process constitutes the cellular basis
of learning and memory (Brown et al., 1990). LTP is typically dependent on
ionotropic NMDA receptor activity (Morris, 2003); however, LTP at mossy fiber
synapses within the CA3 is unique in that it is largely NMDA receptorindependent, and is instead mediated by kainate receptors (Bortolotto et al.,
2003). Previous studies in which the mossy fiber pathway has been disrupted in
mice by chemical inactivation or frank lesions to the CA3 have demonstrated the
importance of this region to several learning and memory paradigms, including

9

fear conditioning and the Morris Water Maze (MWM) (Stupien et al., 2003;
Florian and Roullet, 2004; Kesner, 2007).
Given the importance of GluK4 to mossy fiber LTP, and the importance of mossy
fiber LTP to learning and memory, I sought to elucidate the role of GluK4 in
memory. First, I generated a global GluK4 knockout mouse line by crossing a
transgenic cre line in which cre is expressed in germline cells (The Jackson
Laboratory), and a second mouse line in which exon 16 of GRIK4, the gene
encoding GluK4, was floxed (a generous gift of the Contractor Laboratory at
Northwestern University) (Fernandes et al., 2009). Though GRIK4 mRNA
expression persisted in this line, GluK4 protein expression was undetectable. I
then compared the performance of wild-type and GluK4 knockout mice in a
battery of memory-based tasks. I found, using two forms of a Y-maze task, that
short-term working memory was intact in GluK4 knockout animals. However,
GluK4 knockout animals showed impaired fear memory acquisition during a fear
conditioning task, and impaired spatial memory acquisition and recall during a
MWM task. GluK4 is therefore essential to certain types of associative, but not
working, learning and memory.

GluK4 in Neuropsychiatric Disorders
Learning and memory deficits are often co-morbid with mood disorders (Palomo
et al., 2008), and, indeed, there is mounting evidence from human and animal
studies to suggest a role for aberrant GluK4 expression in schizophrenia and
bipolar disorder. Expression of the NMDA receptor subunit NMDAR1, the AMPA
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subunit GluR1, and the kainate subunits GluK3 and GluK4 were all found to be
decreased at the mRNA level in post-mortem brain tissue from schizophrenics
relative to tissue from normal controls (Porter et al., 1997; Sokolov, 1998).
Neuroleptic treatment in schizophrenic patients restored subunit expression to
normal levels (Sokolov, 1998). Additionally, a genome-wide association study
identified separate single-nucleotide polymorphisms (SNPs) in GRIK4, the gene
encoding the ionotropic glutamate kainate receptor subunit GluK4, that confer
susceptibility to schizophrenia and protection against bipolar disorder,
respectively (Pickard et al., 2006). This association study was initially undertaken
on the basis of clinical observations in a schizophrenic patient who was found to
have a chromosomal breakpoint that disrupted GRIK4 (Pickard et al., 2006).
Furthermore, a deletion mutation within the 3’ untranslated region (UTR) of
GRIK4 not only confers protection against bipolar disorder (Pickard et al., 2008),
but also increases GluK4 mRNA and protein expression (Pickard et al., 2008;
Knight et al., 2011), and enhances hippocampal activation during a face
processing task as assessed by function magnetic resonance imaging (Whalley
et al., 2009a). Finally, GluK2, the kainate receptor subunit that co-precipitates
with GluK4 in the CA3, has also been implicated in bipolar disorder: GluK2
knockout mice display a complex behavioral phenotype that is consistent with
certain facets of the disorder.

Taken together, these data suggest that deficits in GluK4 expression may
contribute to the etiology of schizophrenia and bipolar disorder. I therefore sought
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to characterize the phenotype of the GluK4 knockout mouse line in behavioral
tasks relating to mood and affect. I found that GluK4 knockout mice show
increased exploration of the anxiogenic center zone of an open field, decreased
arousal in an acoustic startle test, and decreased immobility in a forced swim test
relative to wild-type mice, suggesting that GluK4 may mediate anxiety and
depression. Additionally, GluK4 knockout mice showed increased locomotion
relative to wild-type mice, which phenocopies the psychomotor agitation
observed in schizophrenia and bipolar disorder. GluK4 mice also exhibited
decreased prepulse inhibition (PPI), an indication of impaired sensorimotor
gating and a hallmark of patients with schizophrenia and patients in the manic
phase of bipolar disorder (Perry and Braff, 1994; Perry et al., 2001).

GluK4 in Excitotoxicity
In contrast to behavioral disorders such as schizophrenia, which are associated
with insufficient glutamatergic neurotransmission, excitotoxic neurodegeneration
occurs under pathological conditions where there is excessive glutamate release,
such as ischemia and, on a much slower time scale, Alzheimer’s disease (Jacob
et al., 2007). The CA3 region of the hippocampus, where GluK4 expression is
greatest, is highly – and selectively – vulnerable to cell death in some models of
excitotoxicity (Nadler, 1981; Ben-Ari, 1985). Thus, I reasoned that GluK4 might
be involved in excitotoxic neuronal death. Indeed, GluK4 ablation was
neuroprotective in the CA3 following intrahippocampal (IH) kainate injections.
Following hypoxia-ischemia (HI), a murine model of stroke in which animals are
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subjected to unilateral common carotid artery transection and prolonged hypoxia,
GluK4 knockout mice showed marked neuroprotection throughout the
hippocampus.

Using microdissected CA3 tissue from wild-type and GluK4 knockout animals
that had been injected with kainate or vehicle control (phosphate-buffered saline;
PBS), I performed a microarray experiment to analyze the downstream effectors
of GluK4 following excitotoxic insult, and to probe the molecular underpinnings of
neuroprotection in GluK4 knockout animals. From these data and subsequent
biochemical analysis, I found that several pro-apoptotic pathways, most notably
the JNK pathway, were selectively up-regulated in wild-type, but not GluK4
knockout tissue, following kainate injection. The JNK pathway has been widely
implicated in excitotoxic cell death. Mice deficient in JNK3, the neuronal isoform
of JNK, show strong resistance to neurodegeneration following middle cerebral
artery occlusion (MCAO), a murine model of ischemia, and to intraperitoneal (IP)
kainate injection (Brecht et al., 2005). Peptides and small molecules that target
various components of the JNK pathway are also effective in preventing
neurodegeneration following MCAO (Bogoyevitch et al., 2004). Furthermore, the
GluK2 and GluK5 kainate receptor subunits can directly activate the JNK
pathway by forming a signaling complex with post-synaptic density protein 95
(PSD-95) and mixed lineage kinase 3 (MLK3) (Tian et al., 2005; Jiang et al.,
2007). In the context of ischemia, the assembly of this signaling complex
promotes MLK3 autophosphorylation and thereby initiates the kinase cascade
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that leads to JNK activation (Liu et al., 2006). It is therefore likely that GluK4
activation leads to excitotoxic neurodegeneration through the JNK pathway.

Furthermore, I found that JNK pathway activation was increased following vehicle
injection in GluK4 mice compared to wild-type mice, indicating that GluK4 could
play a dual role in JNK pathway activation: under basal conditions, GluK4 may
suppress JNK pathway activation, while under excitotoxic conditions, GluK4 may
promote JNK pathway activation. The precise nature of the relationship between
GluK4 and JNK pathway activation remains to be fully elucidated; however, I
propose several lines of reasoning that may underlie my observations.

GluK4 in Seizure Generation
In addition to triggering excitotoxic neurodegeneration, excessive glutamate
release is thought to underlie medial temporal lobe epilepsy (mTLE) (Sharma et
al., 2007). Kainate administration recapitulates many of the features of mTLE,
including convulsions, hippocampal lesions, and mossy fiber sprouting,
suggesting that kainate receptors may play a role in the pathogenesis of this
disease (Sharma et al., 2007). Furthermore, GluK2 knockout mice are resistant
to kainate-induced seizures (Mulle et al., 1998). I therefore investigated seizure
susceptibility in GluK4 knockout mice relative to wild-type mice, but found that
the paradigm used to instigate and evaluate seizure activity was too variable to
yield significant results. Nevertheless, trends in the data suggest that GluK4
knockout mice may be less susceptible to seizures than wild-type mice at high
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doses of kainate, but more susceptible to seizures at low doses of kainate. These
observations suggest another biphasic role for GluK4, where it may serve to
suppress seizure activity under mildly seizurogenic conditions, but may promote
seizure activity under highly seizurogenic conditions.

The work described herein reveals that a single glutamate receptor subunit with
highly restricted expression serves as a key modulator of anxiety, depressive-like
behavior, memory, and sensorimotor gating on one hand, and excitotoxic cell
death cascades on the other. GluK4 may therefore provide a foothold in
understanding the mechanisms – and treatment – of human neuropsychiatric and
neurodegenerative disorders.
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CHAPTER 2: MATERIALS AND METHODS
Animal Use
For all experiments, mice were 8 – 12 week old males maintained on a 12-hour
light/dark cycle with food and water provided ad libitum. All animal procedures
were approved by the Institutional Animal Care and Use Committee at the
Rockefeller University.

Genotyping
GRIK4 recombination was assessed in DNA preparations from tail samples of
wild-type and GluK4 knockout animals using the primers detailed in Table 2.1
and the following polymerase chain reaction (PCR) conditions: 3 minutes at
94˚C; 30 seconds at 94˚C, 30 seconds at 62˚C, and 30 seconds at 72˚C
repeated for 35 consecutive cycles; and finally 8 minutes at 72˚C. These same
primers and PCR conditions were also used to assess recombination of the
GRIK4 allele in DNA preparations of lung and hippocampus tissue.

To assess the presence of the Cre transgene in the F1 generation of GluK4
knockout animals, the primers detailed in Table 2.1 and the following PCR
conditions were used: 3 minutes at 94˚C; 30 seconds at 94˚C, 1 minute at 51˚C,
and 1 minute at 72˚C repeated for 35 consecutive cycles; and 2 minutes at 72˚C.
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TABLE 2.1. GluK4- and cre-specific primers used to genotype GluK4 knockout
mice
Primer name
GluK4 P1
GluK4 P2
GluK4 P6
Cre forward
Cre reverse

Purpose
Assessing recombination of GRIK4 allele
Assessing recombination of GRIK4 allele
Assessing recombination of GRIK4 allele
Assessing presence of Cre transgene
Assessing presence of Cre transgene

Sequence
GCAGGCTGAACTCTGAGTTT
CCAGAGACAGCACTAGGTGC
GCCTGGGCTAGAGTGAGAC
CCGGTGAACGTGCAAAACAGGCTCTA
CTTCCAGGCGCGAGTTGATAGC

GRIK4 RT-PCR
GRIK4 mRNA expression in wild-type versus GluK4 knockout animals was
expressed by quantitative (q) and non-quantitative reverse-transcriptase (RT)
PCR. mRNA was extracted from fresh-dissected hippocampal tissue using
TRIzol (Ambion) according to the manufacturer’s instructions, and resuspended
in nuclease-free water. Samples were then DNAse-treated using a DNA-free kit
(Ambion). cDNA was synthesized from the purified RNA samples using a
Superscript III kit (Invitrogen) according to the manufacturer’s instructions, with
the following specifications: for non-quantitative RT-PCR, random hexamers
were used as primers, and 0.1M DTT was added to the reaction; for real-time
qRT-PCR, dNTPs were used as primers and DTT was excluded from the
reaction. dNTPs were used for quantitative PCR because they selectively amplify
poly-adenylated (i.e., mature) RNA. Meanwhile, the purpose of the nonquantitative PCR experiment was to determine whether any RNA – mature or not
– was produced in GluK4 knockout animals, so I chose to use random hexamers,
which do not distinguish between immature and mature RNA in these
experiments. DTT acts as an enzyme stabilizing agent in RT-PCR reactions, but
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can interfere with downstream reactions involving SYBR-green and was
therefore excluded from real-time qRT-PCR experiments. For both quantitative
and non-quantitative reactions, the following PCR conditions were used to
generate cDNA from the template RNA samples: 50 minutes at 50˚C; 5 minutes
at 85˚C, after which RNAse H was added to each reaction to remove any
remaining template RNA; and 20 minutes at 37˚C. Reactions in which reverse
transcriptase was omitted were used as negative controls.

For non-quantitative experiments, PCR reactions were carried out using a
standard PCR machine (Eppendorf). The primers used were designed to amplify
distinct, 200 – 300 base pair (bp) regions of GluK4 transcript such that all regions
of the transcript were represented (Table 2.2). Each primer set was used in a
separate reaction mixture with wild-type or GluK4 knockout template cDNA, or
negative controls. All reactions were amplified at the same time using the
following PCR conditions: 3 minutes at 94˚C; 30 seconds at 94˚C, 1 minute at
55˚C, and 30 seconds at 72˚C repeated for 25 cycles; and 10 minutes at 72˚C.
Reaction products were run on a 2% agarose gel and visualized by UV
transillumination.
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TABLE 2.2. Primers used to assess GRIK4 expression using non-quantitative
RT-PCR in wild-type and GluK4 knockout mice
Primer name
GluK4 exons 2 to 4 forward
GluK4 exons 2 to 4 reverse
GluK4 exons 4 to 6 forward
GluK4 exons 4 to 6 reverse
GluK4 exons 6 to 8 forward
GluK4 exons 6 to 8 reverse
GluK4 exons 7 to 9 forward
GluK4 exons 7 to 9 reverse
GluK4 exons 9 to 11 forward
GluK4 exons 9 to 11 reverse
GluK4 exons 10 to 13
forward
GluK4 exons 10 to 13
reverse
GluK4 exons 13 to 15
forward
GluK4 exons 13 to 15
reverse
GluK4 exons 15 to 16
forward
GluK4 exons 15 to 16
reverse
GluK4 exons 16 to 17
forward
GluK4 exons 16 to 17
reverse
GluK4 exons 18 to 20
forward
GluK4 exons 18 to 20
reverse

Purpose
Non-quantitative analysis of GRIK4
mRNA expression, exons 2 to 4
Non-quantitative analysis of GRIK4
mRNA expression, exons 2 to 4
Non-quantitative analysis of GRIK4
mRNA expression, exons 4 to 6
Non-quantitative analysis of GRIK4
mRNA expression, exons 4 to 6
Non-quantitative analysis of GRIK4
mRNA expression, exons 6 to 8
Non-quantitative analysis of GRIK4
mRNA expression, exons 6 to 8
Non-quantitative analysis of GRIK4
mRNA expression, exons 7 to 9
Non-quantitative analysis of GRIK4
mRNA expression, exons 7 to 9
Non-quantitative analysis of GRIK4
mRNA expression, exons 9 to 11
Non-quantitative analysis of GRIK4
mRNA expression, exons 9 to 11
Non-quantitative analysis of GRIK4
mRNA expression, exons 10 to 13
Non-quantitative analysis of GRIK4
mRNA expression, exons 10 to 13
Non-quantitative analysis of GRIK4
mRNA expression, exons 13 to 15
Non-quantitative analysis of GRIK4
mRNA expression, exons 13 to 15
Non-quantitative analysis of GRIK4
mRNA expression, exons 15 to 16
Non-quantitative analysis of GRIK4
mRNA expression, exons 15 to 16
Non-quantitative analysis of GRIK4
mRNA expression, exons 16 to 17
Non-quantitative analysis of GRIK4
mRNA expression, exons 16 to 17
Non-quantitative analysis of GRIK4
mRNA expression, exons 18 to 20
Non-quantitative analysis of GRIK4
mRNA expression, exons 18 to 20
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Sequence
TTCTGGTTCTCATTGTCCCG
AAGATGTCCACTTCGACCTTG
AGGTCGAAGTGGACATCTTTG
GGTGAATCTCTGGAGTTGGAAC
CCAGCAACACCGACATCA
GACACCATCCCCAGTTCAG
CGGGATGACAAGACAGCTAC
GCATGGGATTGGTTGAAAATGG
AGAACTGTGACCATGTGCC
ACCTTCCAATTCTACCATGCG
CAGCCTCATGAACTACCTTCG
TCATTGCCTTCCATCTCCTG
AAGGCAATGACCGATATGAGG
CTGCGTCCCATATGAACTCTG
CTTCTAGCTTATCTGGCGGTC
ACACAGCGGGTAGACAAAG
CGGTGTAATCTCCTGGTCAAC
ATACTCAATGGCAGTCTGGTC
AAGGGCTATGGGATTGGC
CTGATGCTTCTGAGTGTCTGAG

For quantitative experiments, the PCR reactions were carried out using a
Lightcycler 480 (Roche). Each reaction contained wild-type or GluK4 knockout
cDNA, or negative controls. Primers used are outlined in Table 2.3, and were
designed to amplify regions upstream, downstream, and surrounding exon 16 of
GRIK4 mRNA. SYBR green (Applied Biosystems) was used as an index of PCR
product amplification. All reactions were performed in triplicate. Crossing
threshold (CT) values were averaged between technical replicates, and
normalized to reactions in which the appropriate cDNA template was amplified
using primers specific for mouse β-actin (Table 2.3). All subsequent analysis of
fold-change was performed using REST-MCS software (Pfaffl et al., 2002).

TABLE 2.3. Primers used to assess GRIK4 expression using quantitative RTPCR in wild-type and GluK4 knockout mice.
Primer name
GluK4 exons 3 to 4 forward
GluK4 exons 3 to 4 reverse
GluK4 exon 16 forward
GluK4 exon 16 reverse
GluK4 exons 20 to 21
forward
GluK4 exons 20 to 21
reverse
Mouse β-actin
Mouse β-actin

Purpose
Quantitative analysis of GRIK4
mRNA expression, exons 3 to 4
Quantitative analysis of GRIK4
mRNA expression, exons 3 to 4
Quantitative analysis of GRIK4
mRNA expression, exon 16
Quantitative analysis of GRIK4
mRNA expression, exon 16
Quantitative analysis of GRIK4
mRNA expression, exons 20 to 21
Quantitative analysis of GRIK4
mRNA expression, exons 20 to 21
Normalization
Normalization
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Sequence
TCCTGCTTGGCTCTTGAT
GCGGTTGATACGGTTCTTGG
CGGTGTAATCTCCTGGTCAAC
ACACAGCGGGTAGACAAAG
TCTTTGTGGTTCTTATTTGTGG
C
CAGTTCTGTCACCATCTCCTG
CTAAGGCCAACCGTGAAAAG
ACCAGAGGCATACAGGGACA

GRIK4 mRNA Size Assessment and Sequencing
Purified hippocampal cDNA from 3 wild-type and 3 GluK4 knockout animals was
amplified by PCR using a forward primer targeted against the sense strand of
exon 13 (see Table 2.2, primer “GluK4 exons 13 to 15 forward”), and a reverse
primer targeted against the anti-sense strand of exon 20 (see Table 2.2, primer
“GluK4 exons 18 to 20 reverse”). The PCR conditions were as follows: 5 minutes
at 95˚C; 1 minute at 54˚C; 3 minutes at 72˚C; 30 seconds at 95˚C, 1 minute at
54˚C, and 2 minutes at 72˚C, repeated for 35 cycles; and 2 minutes at 72˚C. The
resulting PCR products were run on an agarose gel to compare the size of wildtype versus GluK4 knockout transcript.

Wild-type and GluK4 knockout PCR products were also sequenced by an outside
facility (Genewiz) using the forward primer, and, in separate reactions, the
reverse primer to generate ~1000 bp sequences. Sequences were aligned to the
known GRIK4 mRNA sequence (RefSeq Accession number NM_175481.3)
using DNASTAR software.

Generation of Custom Anti-GluK4 Antibody
A custom GluK4 antibody was generated in rabbits at an outside facility
(Covance) using an immunizing peptide corresponding to amino acids 939 – 956
of the C terminal end of the mouse GluK4 protein,
SPARSEESLEWDKTTNSSEPE. The resulting immune sera were purified
against the immunizing peptide to ensure optimal specificity.
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Western Blotting to Detect GluK4
Fresh-dissected hippocampi from wild-type and GluK4 knockout mice were
homogenized in lysis buffer (25 mM Tris-Cl pH 7.4, 95 mM NaCl, 2% SDS, 10
mM EDTA) supplemented with protease and phosphatase inhibitor cocktails
(Sigma). Protein concentration was determined by spectrophotometer using a
bicinchonic acid (BCA) kit (Thermoscientific) according to the manufacturer’s
instructions. Samples were treated with mercaptoethanol and boiled for 5
minutes at 100˚C. Samples were then run on a denaturing 6% Tris-Glycine gel,
transferred to a PVDF membrane, and blocked in a 5% milk solution dissolved in
Tris-buffered saline with Tween-20. Blots were probed with either the customgenerated GluK4 antibody (1:2000) or an Abcam GluK4 antibody (ab10101;
1:2000). Following overnight incubation in primary antibody, blots were washed,
incubated in the appropriate secondary antibody, washed again, incubated in
chemiluminescent reagent (PerkinElmer), and exposed to film. Band intensity
was quantified using Adobe Photoshop software and normalized to GAPDH
(1:2000, 5% bovine serum albumen; Abcam) from the same blot.

Novel-arm Y-maze
For this and all subsequent behavioral trials, animals were single-housed in the
room in which they were to be tested for at least 5 days prior to the initiation of
the trials, and experimenters were blind to the genotype of the animals during
testing and scoring.
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Mice were placed in a 3-armed Y-maze in which one arm was closed off by an
opaque barrier, and allowed to explore for 5 minutes. The mice were then
removed from the maze and placed in their home cage for 2 minutes, during
which time the barrier was removed from the third arm and the bedding in the
maze was mixed. Finally, mice were placed back in the maze and observed for 5
minutes. The percent time spent in each arm once the barrier was removed was
scored using Ethovision software (Noldus) and analyzed using a two-tailed
Student’s T-test. This and all further behavioral analyses were performed with
Graph Pad Prism software.

Spontaneous Alternation Y-maze
Mice were allowed to freely explore an open-armed Y-maze for 10 minutes. The
order of arm entry was scored by two independent observers, blind to the
genotype of the animals. Alternation was assessed by dividing the number of arm
entry triads in which each arm was visited by the total number of arm visits minus
2, and percent alternation was compared between genotypes using a two-tailed
Student’s T-test.

Fear Conditioning
Fear conditioning experiments took place in a conditioning chamber
(MedAssociates) equipped with a speaker, a house light, and a video camera,
and all trials were video-recorded for subsequent scoring. On the first day of the
test (day 1), mice were placed in a conditioning chamber that had been cleaned
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with an ammonia-based solution and were allowed to habituate to the chamber
for 6 minutes. The final minute of the habituation period was scored to assess
baseline freezing behavior. Mice then received three tone-footshock pairings
(tone, 20 seconds, 85 decibels (dB), 3.5 kilohertz (kHz); footshock, 2 seconds,
0.7 milliamperes (mA)) separated by an inter-trial interval of 60 seconds. After 24
hours (day 2), mice were exposed to the context in which they had initially
received the shock on day 1 (“context stimulus”) for 5 minutes, and the sessions
were video-recorded. The chamber environment was then altered by placing
patterned contact paper on the walls, wire mesh on the floors, and yellow filters
on the lights. The ammonia-based cleaning solution was replaced with an
unscented disinfectant, and the chambers were scented with pure vanilla extract.
Two hours after exposure to the context stimulus, mice were placed in the altered
chambers and exposed to the tone (“cued stimulus”) without the footshock for
two minutes. Freezing behavior for all trials on days 1 and 2 was scored in 5second bins. One-way ANOVAs were used to analyze post-shock freezing for
each tone-shock pairing on day 1. Two-way ANOVAs with Bonferroni post hoc
tests were used to compare freezing behavior between genotypes during oneminutes time bins in the contextual task on day 2, and to compare pre-tone and
tone-elicited freezing behavior during the cued task on day 2.

Incremental Hot Plate
Mice were placed on an incremental hot plate apparatus (IITC Life Science) set
to increase in temperature from 43˚C to 57˚C at a rate of 2.5˚C per minute. A
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two-tailed Student’s T-test was used to compare paw-withdrawal latency
between wild-type and GluK4 knockout mice.

Morris Water Maze (MWM)
MWM experiments were performed in a 1-meter pool filled with room
temperature water made opaque with non-toxic white tempera paint. Distal visual
cues consisting of black and white geometric shapes were placed throughout the
testing room. Mice were initially tested in four 1-minute trials per day for two
consecutive days in a visual platform paradigm, where the platform was 1 cm
above the water level, to assess visual acuity, swimming ability, and motivation to
escape from the water. Mice were then tested in a hidden platform paradigm,
where the platform was submerged 1 cm below the water level, for four trials per
day for four consecutive days. Trials proceeded until mice reached the platform
or, if they were unable to locate it, for 60 seconds, at which point they were
placed on the platform by the experimenter. The pool quadrant in which the mice
were placed was varied across trials for both the hidden and visual platform
assays. Following the final trial on the 4th and final day of hidden platform testing,
a probe trial was carried out to assess spatial memory. The platform was
removed from the pool and the mice were allowed to explore the pool for 2
minutes.

All trials were video recorded and scored using Ethovision software. For visual
platform trials, the latency to reach the platform was compared between
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genotypes on each testing day using a two-way analysis of variance (ANOVA)
with a Bonferroni post-hoc correction. For hidden platform trials, path length and
velocity were averaged across all trials for each mouse and compared by
Student’s T-test. For the probe trials, the difference in quadrant preference
between genotypes was assessed by two-way ANOVA with a Bonferroni posthoc test. Search strategy in hidden platform trials was assessed from traces of
the trajectory from pool entry to platform for each mouse by an experimenter
blind to the genotype of the mice. Assessment criteria were based on those
outlined by Brody and Holtzman (2006). Strategies were categorized as spatial,
non-spatial systematic, or repetitive looping. These strategies are further
described in Chapter 4. Overall differences in search strategies between
genotypes were assessed for each hidden platform day using a Chi-Square test.

Forced Swim Test
Mice were placed in a 4-L transparent beaker that was filled to 20 cm of its 25 cm
height with room temperature water and observed for 6 minutes. All trials were
video-recorded for later scoring. The total amount of time that a mouse spent
immobile over the course of the 6-minute trial was scored by hand every 5
seconds from video recordings and analyzed in one-minute bins. Immobility was
defined as a lack of movement, except for that which was necessary to stay
afloat. The total time spent immobile over the course of the trial was analyzed by
a two-tailed Student’s T-test. The contribution of time, genotype, and the
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interaction between time and genotype to overall variation was assessed by twoway ANOVA coupled with a Bonferroni post-hoc test for multiple comparisons.

Open Field Test
Two open field paradigms were used: one to assess anxiety, and one to assess
locomotor behavior. In the anxiety paradigm (referred to in the text as “short / lit”),
the open field test was conducted in an evenly lit 46 cm x 46 cm arena with a
white floor and black walls. Mice were individually placed in the arena such that
they were facing a wall, and observed for 5 minutes. The arena was cleaned with
70% ethanol between trials. All trials were tracked and scored with Ethovision
software (Noldus). For scoring purposes, the arena was divided into central and
peripheral zones, where the center and periphery represented 36% and 64% of
the total area of the arena, respectively. Scored measures included total number
of center entries, percent time spent in center versus periphery, total distance
traveled, and average velocity. Differences in each measure between wild-type
and GluK4-knockout mice were analyzed by two-tailed Student’s T-tests.

In the locomotor paradigm (referred to in the text as “long / dark”), the open field
test was conducted in a completely dark room. Light meter readings indicated
that ambient light levels were 0 relative light units (RLU). The open field
chambers used in this paradigm (Accuscan) were equipped with a laser
photobeam tracking system to assess vertical and horizontal beam breaks. The
arena was divided into central and peripheral zones such that the center
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represented 40% of the total area, and the periphery represented 60% of the
total area (the constraints of the tracking software made it impossible to exactly
reproduce the zone distributions of the short / lit paradigm). Animals were
observed for 1 hour, and behavior was scored in 5-minute bins using Fusion 3.2
Software (Accuscan). Scored measures included number of center entries,
percent time spent in the center zone, and distance traveled. Differences in each
measure over time between wild-type and GluK4-knockout mice were assessed
by a two-way repeated measures ANOVA with Bonferroni post-hoc analysis.

Acoustic Startle and Prepulse Inhibition (PPI)
Mice were tested in SR-LAB startle response system chambers (San Diego
Instruments) equipped with a speaker and a Plexiglas restraint chamber mounted
on a piezoelectric accelerometer unit. Stimuli were presented in five blocks, and
each stimulus was followed by a non-stimulus period of white noise (background)
of 65 dB. In the first block, animals were presented with 5 single pulses of 120 dB
to test their basal startle response. In the second block, animals were presented
with 4 pulses of 80, 90, 100, 110, and 120 dB, ordered pseudo-randomly, to
assess startle threshold. In the third block, animals were presented with 120 dB
pulses preceded by a prepulse that was 3, 6, or 12 dB louder than the
background. Each prepulse / pulse combination was presented 9 times, in
pseudo-random order. Single 120 dB pulses were also presented 9 times,
interspersed with prepulse / pulse pairs. In the fourth block, pulse intensity was
maintained at 120 dB, prepulse was maintained at 6 dB above background, and
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the inter-stimulus interval (ISI) between the prepulse and pulse was varied. The
ISIs assayed were 25, 50, 100, 200, and 500 milliseconds (ms), and each ISI
was presented 3 times in pseudo-random order, interspersed with 120 dB single
pulses. In the fifth block, animals were again presented with 5 single pulses of
dB. The startle response, Vmax, was recorded using SR-LAB software (San
Diego Instruments).

To assess the startle threshold, the startle response to each tone intensity in the
second block was averaged for each mouse, and compared between genotypes
across tones using a two-way repeated-measures ANOVA with a Bonferroni
post-hoc test. In the third block, the percent PPI was calculated for each prepulse
intensity using the following equation: 100 – ((average Vmax for prepulse
intensity in question / average Vmax within block 3 for single 120 dB pulse) *
100). Percent PPI was compared between genotypes across prepulse intensity
by two-way repeated-measures ANOVA with a Bonferroni post-hoc test. In the
fourth block, the percent PPI was calculated for each ISI using the following
equation: 100 – ((average Vmax for ISI in question / average Vmax within block 4
for single 120 dB pulse) * 100). Percent PPI was then compared between
genotypes across ISI by two-way repeated-measures ANOVA with a Bonferroni
post-hoc test.
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Stereotaxic Injections
For IH stereotaxic injections, animals were anesthetized with 2.5% avertin (0.02
mL/g of body weight) and atropine (0.6 mg/kg of body weight). Animals were then
placed in a stereotaxic apparatus (Stoetling) and injected over the course of 60
seconds with 300 nanoliters (nL) PBS or 0.15 nanomoles (nm) kainate in 300 nL
PBS. Injection coordinates were as follows: -2.5 mm from Bregma on the
anterior-posterior axis; 1.7 mm from the midline on the medial-lateral axis; and
1.7 mm dorsal-ventral from the surface of the skull. For stereology experiments,
animals were injected unilaterally. For microarray and biochemistry experiments,
animals were injected bilaterally. Injections were performed with a 2.5 µL
Hamilton syringe equipped with a 33-gauge blunt needle and controlled by an
automated microinjection pump (World Precision Instruments). After injection, the
needle was retracted by 0.1 mm and left in place for 2 minutes to allow injected
material to diffuse. Animals were then injected IP with 0.03 mL buprenex (0.03
mg/kg of body weight) for analgesia and 500 mL sterile 0.9% saline for
rehydration, and they were allowed to recover on a heating pad.

Hypoxia-Ischemia (HI)
Animals were maintained under deep isoflurane anesthesia during surgery. The
left common carotid artery was exposed and gently separated from the vagus
nerve. The artery was then ligated at two points several millimeters apart with 6-0
silk sutures, and transected between the ligation points. Following surgery, mice
were injected IP with 0.03 mL Buprenex (buprenorphine HCl; 0.03 mg/kg of body
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weight) and 500 mL sterile 0.9% saline, and allowed to recover for 40 minutes on
a heating pad. Animals were then transferred to a hypoxic chamber maintained
at 8% O2 and 92% N2 for 45 minutes at 37˚C (Vannucci et al., 2001).

Stereology
24 hours after IH kainate injection or HI, animals were perfused with 15 mL icecold 0.9% saline followed by 15 mL of ice-cold 4% paraformaldehyde (PFA).
Brains were post-fixed overnight in 4% PFA, cryoprotected for 24 hours in 30%
sucrose in 0.1 M phosphate buffer, frozen in powdered dry ice, and stored at 80˚C. Thin sections were collected on a cryostat and stored at -20˚C in freezing
medium (30% glycerol, 30% ethylene glycol, 40% 0.1 M phosphate buffer) until
use. For tissue from IH-injected animals, 20 µm sections were collected in 12well plates such that each plate contained a range of sections that were 240 µm
apart. Extensive tissue damage sustained by HI-treated animals made it
necessary to slice tissue at 30 µm, such that sections were 360 µm apart in each
well of a 12-well plate.

Fixed free-floating brain sections from one well were mounted on glass slides
using a gelatin-based mounting medium and dried overnight at room
temperature. Sections were stained in a solution of 0.00005% Fluorojade C
(FJC) and 0.0001% 4’,6-Diamidino-2-Phenylindole (DAPI) (Schmued et al.,
2005), and visualized using an Axiovert 200 inverted epifluorescence microscope
(Carl Zeiss, Inc.). All sections were imaged at high resolution and 50x
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magnification. Exposure time and gain were consistent for each stain between all
sections from all animals.

Cell death was quantified using NIH Image J software. Hippocampal subregions
were identified and outlined by observation of DAPI staining. Subregion outlines
were overlaid onto corresponding FJC images. The FJC images were split into
their component red, green, and blue color channels, and the green channel was
selected for further processing. Images were calibrated in µm, and then
thresholded using the triangle algorithm to highlight FJC-positive cells. This
algorithm was chosen because it consistently yielded a higher signal-to-noise
ratio than the other available algorithms. Image splitting, calibrating, and
thresholding were all carried out using an automated macro to ensure that image
processing was consistent across sections. Experimenters were blind to the
genotype and treatment of the animals during image processing. The area of
FJC-positive staining within each hippocampal subregion was recorded and
normalized to the total number of slices quantified. Differences in FJC area
between genotypes were analyzed for each subregion using a two-tailed
Student’s T-test.

Microarray Sample Preparation and Array Hybridization
24 hours after bilateral IH injection of PBS or kainate, animals were killed by
cervical dislocation. The hippocampus from the left hemisphere was quickly
removed and left intact, while the hippocampus from the right hemisphere was
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microdissected with sterile tools on ice to isolate the hippocampal subfields.
Tissue was immediately frozen in sterile tubes on dry ice and stored at -80˚C
until use.

Total RNA and total protein were isolated simultaneously using TRIzol according
to the manufacturer’s instructions. Briefly, tissue samples were homogenized in
TRIzol and incubated for 10 minutes at room temperature. Following the addition
of chloroform, samples were centrifuged at 12,000 x g for 15 minutes at 4˚C. The
aqueous layer, containing total RNA, and the organic layer, containing total
protein, were collected separately for further processing. The aqueous layer was
incubated at 20˚C for 1 hour in isopropanol supplemented with glycogen,
centrifuged at 12,000 x g for 15 minutes at 4˚C, washed with 70% ethanol, and
pelleted at 7,500 x g for 5 minutes at 4˚C. The RNA pellet was then air-dried for 5
minutes at room temperature, and resuspended in nuclease-free water at 55˚C.
Meanwhile, the organic layer was cleared of DNA by ethanol precipitation
followed by sedimentation at 2000 x g for 5 minutes at 4˚C. The proteins in the
resulting supernatant were precipitated with isopropanol, sedimented at 12,000 x
g for 10 minutes at 4˚C, and washed 3 times in 0.3 M guanidine hydrochloride in
95% ethanol. The protein pellet was then incubated in ethanol for 20 minutes at
room temperature, centrifuged at 7,500 x g for 5 minutes at 4˚C, vacuum-dried
for 5 minutes, and dissolved in a buffer containing 25 mM Tris-HCl, 95 mM NaCl,
2% SDS, and 10 mM EDTA supplemented with protease and phosphatase
inhibitors. Protein samples were stored at -80˚C until use.
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All RNA samples were purified with an RNeasy mini kit (Qiagen) according to the
manufacturer’s instructions. The quality and concentration of all RNA samples
was determined using a Bioanalyzer (Agilent). Any sample with an RNA integrity
number below 8, or a concentration below 40 nanograms (ng) / µL – the minimal
criteria required for microarray analysis – was subjected to further purification
with an RNeasy MinElute kit (Qiagen).

One-step RT-PCR using was performed on all hippocampal and CA3 RNA
samples with primers specific to heat shock protein 27 (Hsp27; RefSeq
accession number NM_103560; Table 2.4) to investigate whether the samples
that were supposed to receive kainate had actually received it. Hsp27 is a heatshock-protein-encoding gene that is highly up-regulated in the context of
excitotoxicity (Hunsberger et al., 2005; van der Weerd et al., 2010). CA3 samples
were further analyzed by one-step RT-PCR using CA1- and DG-specific primers
(Table 2.4) to assess contamination from neighboring hippocampal sub-regions. I
assessed multiple primer pairs directed against a host of region specific genes
that were first identified by Lein et al. (Lein et al., 2004). These primer pairs were
compared in CA3, DG, and CA1 samples, and the most robust and tissuespecific primer pairs were selected for further analysis. The CA1-specific gene
selected was nephroblastoma overexpressed gene (Nov; RefSeq Accession
number NM_010930), and the DG-specific gene selected was desmoplakin (Dsp;
RefSeq Accession number NM_023842.2).
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TABLE 2.4. Primers used to evaluate microarray RNA samples.
Primer name
Hsp27 forward
Hsp27 reverse
DG forward
DG reverse
CA1 forward
CA1 reverse

Purpose
Semi-quantitative analysis of Hsp27 expression
as indication of kainate-induced excitotoxicity
Semi-quantitative analysis of Hsp27 expression
as indication of kainate-induced excitotoxicity
Semi-quantitative analysis of Dsp expression
as indication of DG contamination
Semi-quantitative analysis of Dsp expression
as indication of DG contamination
Semi-quantitative analysis of Nov expression
as indication of CA1 contamination
Semi-quantitative analysis of Nov expression
as indication of CA1 contamination

Sequence
CTGGACGTCAACCACTTCG
CTGCCTTTCTTCGTGCTTG
CCTGTGATGCGTATCAGAAAAG
TGTAAAGGGCTCGCATTTG
CCCGAGGAAGTAACAGACAAG
GAGACACTGAAACTCCACCTG

One-step RT-PCR was carried out using a OneStep RT-PCR kit (Qiagen). PCR
conditions were optimized for each primer pair to determine the cycle number
and template RNA concentration required to achieve optimal signal. All primer
pairs ultimately required 30 PCR cycles, and 25 ng of RNA. The following PCR
conditions were used: 30 minutes at 50˚C; 15 minutes at 95˚C; 45 seconds at
94˚C, 45 seconds at 53˚C, and 1 minute at 72˚C, repeated for 30 cycles. The
resulting PCR products were run on an agarose gel alongside a DNAladder
(GeneRuler), and analyzed semiquantitatively: PCR band intensity was assessed
using Photoshop, and normalized between gels using the same band on the
accompanying DNA ladder. (Pilot experiments in which the one-step RT-PCR
reactions were multiplexed with β-actin primers to facilitate within-sample
normalization were largely unsuccessful: β-actin was far more abundant than any
of the other genes amplified, and the PCR amplification of β-actin would saturate
– and therefore prove useless for quantification – in far fewer cycles than the
other genes.) In experiments where CA3 samples were assessed for
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contamination by neighboring sub-regions, a positive control consisting of
purified DG RNA or CA1 RNA amplified by the DG- or CA1-specific primer pair
was included in each gel. CA3 samples with the lowest levels of contamination
were selected for further processing.

Purified RNA samples that had been assessed for contamination and kainate
injection as appropriate were pooled in equal proportions. 3 samples were pooled
for each of the 8 conditions described in Chapter 7, and submitted to the
Genomics Resource Center at the Rockefeller University for amplification,
labeling, and chip hybridization. Briefly, biotin-UTP-labeled cRNA was generated
and amplified by T7 linear amplification using a MessageAmp Premier RNA
Amplification kit (Applied Biosystems), and hybridized to a MouseRef-8 v.20
Expression Bead Chip (Illumina). This chip includes probes for ~25,600 RefSeq
transcripts, corresponding to 19,100 unique genes from the mouse genome.

Microarray Data Analysis
Raw signals from the Illumina chip were exported into Genespring software. All
signals were thresholded as follows: the background was set to 70, the lower
cutoff for a present call was set to 0.8, and the upper cutoff for an absent call was
set to 0.6. Thresholded signals were then scaled to the median, and transformed
to a log2 scale. Fold change was calculated as the ratio between conditions as
appropriate.
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For Database for Annotation, Visualization and Integrated Discovery (DAVID)
analysis, fold change after kainate injection was calculated relative to PBS, and
compared between genotypes to extract genes that were changed by greater
than |2|-fold. This analysis resulted in three gene lists: genes that were changed
by greater than |2|-fold in both genotypes, genes that were changed by greater
than |2|-fold in wild-type samples alone, and genes that were changed by greater
than |2|-fold in knockout samples alone. Each list was then input into DAVID and
compared against the Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway database (Huang et al., 2008).

For Gene Set Enrichment Analysis (GSEA), all probe sets meeting the threshold
conditions set in Genespring were ranked for each genotype according to their
fold-change after kainate injection relative to PBS. Wild-type and GluK4 knockout
gene lists were analyzed separately using the GSEAPreranked setting in GSEA,
and compared at 100 permutations against the Biocarta pathway database
(Subramanian et al., 2005). Gene sets from the Biocarta database that were
larger than 800 genes, or smaller than 6 genes, were excluded from analysis.
The chip annotations file that provides the gene names associated with the
microarray probe identification numbers listed in the Genespring output was
downloaded from the Illumina website (MouseRef8_V2_0_R2_11278551_A). For
probes that were represented more than once on the microarray chip, the
instance in which it yielded the highest fold-change value was selected for
analysis (max_probe setting in GSEA).
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Western Blotting to Detect JNK Pathway Components
Western blotting to analyze JNK pathway components was performed as
described above, with several modifications. Total protein and RNA were
simultaneously extracted from fresh-dissected samples using TRIzol. 30 µg of
CA3 protein per lane were treated with mercaptoethanol, boiled for 5 minutes,
and loaded onto a 10% Tris-Glycine polyacrylamide gel. Proteins were
transferred to a PVDF membrane, and membranes were blocked and incubated
in primary as above. Anti-phosphorylated MKK4, anti-JNK, anti-phosphorylated
JNK, anti-cJun, anti- phosphorylated cJun, and anti-phosphorylated ATF-2
antibodies were all purchased from Cell Signaling and used at 1:1000 in the
dilution buffer recommended by the manufacturer. Anti c-Fos was purchased
from Calbiochem and used at 1:250 in 5% milk. Blots were then probed with
secondary antibodies, incubated in chemiluminescent reagent, and quantified as
above.

Intraperitoneal (IP) Kainate Injections
10 mM kainate solution in saline was prepared fresh each day that it was
administered. Up to 6 mice were injected on a given experimental day, using one
of several injection paradigms: (1) an initial dose of 30 mg/kg kainate, followed by
two doses of 15 mg/kg at 45 minute intervals; (2) an initial dose of 15 mg/kg
kainate followed by two doses of 5 mg/kg at 10 minute intervals; (3) an initial
dose of 15 mg/kg, followed by a single dose of 5 mg/kg after 20 minutes; or (4) a
single dose of 15 mg/kg. In injection paradigm (1), mice were observed for 4
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hours following the initial injection; in all other paradigms, mice were observed for
2 hours. After the observation period, all mice were rehydrated with 500 mL of
sterile saline and allowed to recover on a heating pad overnight.

Seizures were hand-scored during the observation period using a 0 – 6 scale first
developed by Racine (Racine, 1972). The scale used for the experiments herein
included slight modifications as described (McKhann et al., 2003; McLin and
Steward, 2006). At level 0, mice do not show any abnormal behavior; at level 1,
mice cease to explore, sniff, and groom, and become motionless; at level 2, mice
adopt a rigid posture, stretching their bodies out and erecting their tails; at level
3, mice begin to show myoclonic jerks of the head and neck, and may rear into a
sitting position; at level 4, mice exhibit forelimb clonus, running clonus, or rearing
and falling broken by periods of total stillness; at level 5, mice show continuous
level 4 seizures; and at level 6, mice exhibit violent bouncing seizures that
progress to a loss of posture tone and death if persisting.

Data from injection paradigms that were repeated over several days were
combined for analysis. The effects of genotype and time were compared by twoway ANOVA with a Bonferroni post-hoc test.
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CHAPTER 3: GENERATING GLUK4 KNOCKOUT ANIMALS
Mouse Crosses
GluK4 knockout animals were generated by crossing mice homozygous for a
GRIK4 allele in which exon 16 was floxed (GluK4-floxed mice; generously
provided by the Contractor Laboratory at Northwestern University) (Fernandes et
al., 2009) with mice homozygous for a transgene encoding cre-recombinase
under the control of an EIIA promoter (Figure 3.1). The EIIA promoter is active in
the early mouse embryo, allowing for cre-mediated recombination in many
tissues, including germ cells. Animals resulting from this cross transmit the
recombined GRIK4 allele to their progeny in a global, cre-independent manner.
All first filial generation (F1) offspring were heterozygous for the floxed,
recombined (FR) GRIK4 allele as well as the EIIA cre transgene. Founder F1
offspring were then mated to yield the allelic frequencies outlined in Table 3.1 by
the second filial (F2) generation.

F2 mice that were homozygous for the FR GRIK4 allele, regardless of Cre
transgene status, (Table 3.1, highlighted rows) were selected for propagation of
the GluK4 knockout line. All knockout animals had a mixed C57Bl/6 / 129SvE
background. Animals homozygous for the wild-type (+) GRIK4 allele but
maintained on the same background as GluK4 knockout mice are referred to
herein as wild-type mice.
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FIGURE 3.1. Schematic of GluK4 knockout strategy. Exon 16 of GRIK4 was
floxed GluK4-floxed mice. Crossing these mice with an EIIA-cre line, where cre is
expressed in the germline, resulted in a global, cre-independent GluK4 knockout
line.
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TABLE 3.1. Expected Mendelian ratios of F2 offspring resulting from crosses of
founder F1 mice.
EIIA Cre Transgene*

GRIK4 allele**

Cre/Cre
Cre/Cre
Cre/+
Cre/+
Cre/Cre
+/+
Cre/+
+/+
Cre/Cre

FR/FR
FR/+
FR/FR
FR/+
+/+
FR/FR
+/+
FR/+
+/+

Expected percentage of
offspring
6.25%
12.50%
12.50%
25.00%
6.25%
6.25%
12.50%
12.50%
6.25%

* “+” refers to the wild-type allele, “Cre” refers to the EIIA Cre transgenic allele;
** “+” refers to the wild-type allele, “FR” refers to the floxed, recombined allele.

Assessing Global Cre-mediated GRIK Recombination
Cre-mediated recombination of the floxed GRIK4 allele was assessed using a
three-primer PCR strategy. A forward primer, P2, and a reverse primer, P1, were
designed to flank the first (downstream) loxP site, such that P2 was downstream
of the loxP site and P1 was upstream. The region recognized by P1 was located
between the two loxP sites, such that it would be obviated by successful cremediated recombination. A third reverse primer, P6, was targeted upstream of
the second loxP site (Figure 3.2).
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FIGURE 3.2. Schematic of genotyping strategy for GluK4 knockout mice. P2
is a forward primer, and P1 and P6 are both reverse primers. (A) The wild-type
allele yields a 264 bp P2-P1 PCR product and a 1500 bp P2-P6 product. (B) The
floxed, unrecombined allele yields a 388 bp P2-P1 product, and a 1700 bp P2-P6
product. (C) The floxed, recombined allele yields a 422 bp P2-P6 product. P1 is
targeted against a region between the two loxP sites, such that successful
recombination eliminates that region and, thus, the P2-P1 product.
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Using this genotyping strategy, PCR products of the sizes outlined in Table 3.2
were obtained for the various genotypes assessed.

TABLE 3.2. Expected size of genotyping PCR products.
Wild-type

F/F (homozygous
floxed, unrecombined)

P2-P1 PCR product size

264 bp

388 bp

P2-P6 PCR product size

1500 bp

1700 bp

GluK4 knockout
(homozygous floxed,
recombined)
N/A: P1 recognition site
excised
422 bp

To determine whether cre-mediated recombination of GRIK4 had occurred
globally, DNA extracts from hippocampus, cortex, lung, and tail from wild-type
versus heterozygous FR / + mice from the founder F1 generation were analyzed
using the 3-primer PCR strategy described above. As predicted, the recombined
GRIK4 allele was present in all FR / + heterozygote tissues, and absent in all
wild-type tissues (Figure 3.3).
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FIGURE 3.3. Assessing cre-mediated recombination of GRIK4 in various
tissues from GluK4-floxed, and GluK4 FR / + heterozygote mice. (A) The
floxed, unrecombined allele, which appears here as a ~1700 bp band
corresponding to the P2-P6 PCR product, is present in all tissues assessed in
GluK4-floxed mice. The faint lower band (~400 bp) represents the P2-P1 PCR
product, but is not favored in this reaction. (B) Recombination of the floxed
GRIK4 allele has occurred in all GluK4 FR / + heterozygote tissues assessed.
The upper band (~1500 bp) represents the floxed, unrecombined allele; the lower
band (~400 bp) represents the recombined allele.
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Characterizing GRIK4 mRNA Expression
The GRIK4 gene yields a 3488 bp transcript with 21 exons (RefSeq accession
number NM_175481.5). The coding region extends from positions 201 to 3071,
which overlaps with exons 3 – 21. Exon 16, which is floxed in the GluK4-floxed
animals provided by the Contractor laboratory, encodes the pore-forming M2 ploop region of GluK4 (Fernandes et al., 2009) (see Figure 1.1).

The Contractor laboratory had shown previously that a global GluK4 knockout
mouse, generated using a germline-expressed cre line similar to the EIIA cre line
used here, was both a transcriptional and translational null (Fernandes et al.,
2009). However, they assessed GRIK4 mRNA expression using a primer pair
designed to amplify the excised exon 16, and therefore did not exclude the
possibility that a GRIK4 transcript containing the regions up- or downstream was
still being expressed.

To evaluate this possibility, I designed primer sets that were targeted throughout
the GRIK4 transcript such that all exons within the coding region were
represented (exons 2 – 20). I then used these primer sets to perform RT-PCR on
RNA purified from wild-type and GluK4 knockout hippocampus homogenates.
The PCR products were run on an agarose gel and visualized by UV illumination.
Bands representing all amplified regions of GRIK4 were present in wild-type
samples. Surprisingly, the same bands were also present in GluK4 knockout
samples, with the exception of those with either a forward or a reverse primer in
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exon 16 (Figure 3.4a). To ensure that the presence of bands in the GluK4
knockout samples was not the result of genomic DNA contamination, I ran the
same PCR reactions without including reverse transcriptase. No bands were
observed in these conditions (Figure 3.4a).

To further explore GRIK4 mRNA expression in GluK4 knockout animals, I ran
RT-PCR on wild-type and GluK4 knockout hippocampal extracts using a forward
primer located in exon 13, and a reverse primer in exon 20, such that the
resulting PCR product would encompass exon 16. The predicted size of the PCR
product from the wild-type GRIK4 allele is 940 bp, and a band of this size was
indeed observed in wild-type samples. The band observed in knockout samples
was approximately 200 bp smaller, a decrease corresponding to the predicted
size of exon 16 (173 bp; Figure 3.4b). PCR products from wild-type and GluK4
knockout samples were then sent to an outside facility (Genewiz) for sequencing.
Aligning the resulting sequences with the predicted GRIK4 mRNA sequence
indicated that GluK4 knockout samples were indeed missing exon 16, but that
the surrounding regions were intact. Furthermore, sequencing revealed that the
deletion of exon 16 was in frame, and that there were no premature stop codons
in the sequenced region of GluK4 knockout mRNA. Taken together, these results
indicate that GluK4 knockout animals are not, in fact, transcriptional knockouts.
Instead, they produce a truncated GRIK4 mRNA product that is missing exon 16.
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FIGURE 3.4. GRIK4 mRNA is intact in GluK4 knockout mice. (A) Nonquantitative RT-PCR using primer pairs that, together, covered all coding exons
of GRIK4, revealed that GRIK4 mRNA was intact in GluK4 knockout mice. Only
the region corresponding to the floxed exon 16 is missing. (B) A product
encompassing the region corresponding to exon 16 was ~200 bp smaller in
GluK4 knockout samples than in wild-type samples, consistent with the size of
exon 16. (C) Quantitative RT-PCR using primer pairs designed to amplify exons
3-4, exons 20-21, or exon 16 indicated that GRIK4 mRNA is expressed at the
same levels in wild-type and GluK4 knockout hippocampal tissue. Once again,
only the region corresponding to exon 16 appeared to be missing. Bars represent
mean ± SEM. * p < 0.05. WT, wild-type; KO, GluK4 knockout; + RT, reactions
including reverse transcriptase; - RT, reactions excluding reverse transcriptase;
Ex, exons.
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The possibility remained, however, that the modified GRIK4 mRNA produced by
the GluK4 knockout animals was expressed only at very low levels, rendering the
animals functional – if not true – knockouts. To address this, I performed
quantitative RT-PCR on hippocampal extracts from wild-type mice and GluK4
knockout mice. Three primer sets were used in separate experiments: one set
that amplified exons 3 – 4, corresponding to the coding region of the GRIK4
transcript that is farthest downstream in the 5’ direction; one set that amplified
exon 16; and one set that amplified exons 20 – 21, corresponding to the coding
region of the GRIK4 transcript that is farthest upstream in the 3’ direction. cDNA
levels in each reaction were detected by SYBRgreen in a Roche Lightcycler 480
real time RT-PCR system. While expression of the amplified region surrounding
exon 16 was significantly down-regulated (p = 0.042) and essentially abolished in
GluK4 knockout samples relative to wild-type samples, expression of exons 3 – 4
and exons 20 – 21 did not differ significantly from wild-type levels (p = 0.697 and
p = 0.846, respectively; Figure 3.4c). These data indicate that GluK4 knockout
animals are not transcriptional nulls: they produce a modified GRIK4 transcript
that lacks exon 16, but is otherwise intact, and they express this modified
transcript at the same levels that wild-type animals express the wild-type
transcript.
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Characterizing GluK4 Protein Expression
The fact that GluK4 knockout animals were not transcriptional nulls raised the
possibility that they were not true translational nulls, as they were reported to be
by the Contractor laboratory (Fernandes et al., 2009). Initial attempts to assess
whether GluK4 knockout animals expressed GluK4 protein yielded inconsistent
results: western blots using commercially available GluK4 antibodies had such
high background that it was difficult to disambiguate aspecific bands from those
corresponding to GluK4.

To obviate this issue, I commissioned the production of a custom, polyclonal
GluK4 antibody (Covance). The immunizing peptide used to generate the
antibody, SPARSEESLEWDKTTNSSEPE, corresponds to amino acids 939 –
956 of the C terminal end of the mouse GluK4 protein. This peptide had
previously been used in two separate studies to generate GluK4 antibodies
(Fogarty et al., 2000; Darstein et al., 2003), and was chosen because its
sequence has high homology between mouse, rat, and human isoforms of
GluK4, but low homology to other ionotropic glutamate receptor subunits. The
resulting polyclonal antibody was affinity-purified against the immunizing peptide
to remove non-specific antibody species. Using this antibody, it was possible to
distinguish a band corresponding to the predicted 108 kilodalton (kDa) molecular
weight of GluK4 in wild-type hippocampal extracts. However, this band was not
observed in GluK4 knockout extracts, nor were any additional bands that might
correspond to modified forms of GluK4 (Figure 3.5a).
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Because the custom GluK4 antibody recognizes the C-terminus of the GluK4
protein, it was still possible that GluK4 knockout mice might express one or more
modified forms of GluK4 in which the C-terminus was absent but other areas of
the protein were intact. To assess this, western blots were performed on the
same wild-type and GluK4 knockout hippocampal extracts using a commercially
available antibody directed against amino acids 59 – 73 of the N-terminus of
GluK4 (ab10101; Abcam). Like the other commercially available GluK4
antibodies, this antibody yielded high background. However, upon over-exposing
the blots, it was possible to observe a band corresponding to the size of GluK4 in
wild-type extracts that was absent in GluK4 knockout extracts. No additional
bands were observed in GluK4 knockout blots using this antibody (Figure 3.5b).
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FIGURE 3.5. GluK4 protein is undetectable by western blot in GluK4
knockout animals. Western blots of wild-type and GluK4 knockout wholehippocampus homogenates using a custom generated (A) or commercially
available (B) anti-GluK4 antibody indicated that a band corresponding to the
predicted size of GluK4 (108 kDa) was missing in GluK4 knockout mice.
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Taken together, these results suggest that GluK4 knockout animals are ultimately
translational nulls, despite the fact that they are not transcriptional nulls. It is
likely that the excision of exon 16, which corresponds to the pore-forming p-loop
of GluK4, results in either an unstable protein that gets targeted for degradation,
or a stable protein that is unable to pass a critical checkpoint during kainate
receptor assembly, and thus gets targeted for degradation.
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CHAPTER 4: GLUK4 IN LEARNING AND MEMORY
GluK4 knockout mice show reduced LTP (Catches et al., 2012), a cellular
process that is crucial to learning and memory. GluK4 expression is also highest
within the CA3 region of the hippocampus, an area that is involved in memory
acquisition and retrieval (Hunsaker et al., 2009). I therefore investigated whether
GluK4-deficient animals demonstrated learning or memory impairments.

GluK4 Ablation Does Not Affect Performance in Novel-arm or Spontaneous
Alternation Y-maze Tests
Working (short-term) memory was assessed by novel-arm Y-maze and
spontaneous alternation Y-maze. In the novel-arm Y-maze task, mice were
initially placed in a 3-armed Y-maze in which one arm was blocked, and allowed
to acclimatize. The block was then removed from the third arm, thereby creating
a novel environment for the mice to explore. Because mice are inherently curious
about novel environments, mice with intact working memory should spend
proportionally more time in the novel arm than in the two arms that had initially
been open (Hughes, 2004). Both wild-type (n = 5) and GluK4 knockout (n = 6)
mice favored the novel arm to the other arms, with no significant difference in the
percent time spent in the novel arm (Student’s T-test, p = 0.6721; Figure 4.1a) or
either of the other arms (Student’s T-test, p = 0.8436 and p = 0.4399; Figure
4.1a).
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In the spontaneous alternation Y-maze task, mice were allowed to freely explore
a 3-armed Y-maze. Because, once again, mice prefer novel environments, mice
with intact working memory should continuously seek the least-recently-visited
arm as they move about the maze, and should therefore alternate between the
arms in triads – that is, arm A, followed by arm B, followed by arm C. The
proportion of triads in each trial is measured as percent alternation. No significant
difference in percent alternation was observed between wild-type and GluK4
knockout mice (wild-type, n = 13; GluK4 knockout, n = 12; student’s T-test, p =
0.4028; Figure 4.1b).

Taken together, the data from the novel-arm Y-maze and the spontaneous
alternation Y-maze suggest that GluK4 ablation does not affect working memory.
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FIGURE 4.1. GluK4 knockout mice do not show working memory
impairments in Y-maze tasks. (A) In a novel-arm Y-maze, wild-type (n = 5) and
GluK4 knockout mice (n = 6) showed equal preference for the novel arm (Arm C;
p = 0.6721). (B) In a spontaneous alternation Y-maze, wild-type (n = 13) and
GluK4 knockout mice (n = 12) did not differ in their % alternation (p = 0.4028).
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Fear Memory Acquisition is Impaired in GluK4 Knockout Mice
In Pavlovian fear conditioning paradigms, mice learn to associate a neutral
conditioned stimulus (CS) and an aversive unconditioned stimulus (US), such
that the CS alone evokes a fear response. The CS can be defined as a cue, such
as a tone, that accompanies the US, or the context in which the mice initially
receive the US. Cued and contextual fear conditioning are thought to be
amygdala- and hippocampus-dependent, respectively (Maren, 2008). Targeted
disruption of the afferent mossy fiber pathway in the GluK4-rich CA3 region
impairs the acquisition and consolidation of contextual fear memory (Daumas et
al., 2004), a finding that raises the possibility that GluK4 might be involved in
contextual fear conditioning. Furthermore, ablation of the GluK2 kainate receptor
disrupts cued fear memory and reduces synaptic potentiation in the lateral
amygdala (Ko et al., 2005).

Based on this evidence, I investigated the role of GluK4 in both cued and
contextual fear memory. The cued CS consisted of a tone (3.5 kHz, 85 dB; “cued
stimulus”), and the contextual stimulus consisted of the initial environment in
which the mice were presented with the US (“context stimulus”). The US
consisted of a footshock delivered through floor rods connected to a shock
generator. On day 1, mice were presented with three tone-shock pairings. Both
wild-type and GluK4 knockout mice demonstrated immediate post-shock
freezing, but while freezing behavior increased steadily during successive toneshock pairings in the wild-type cohort, it did not increase significantly in the
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knockout cohort (One-way ANOVA (tone): for wild-type mice F = 8.455, p =
0.0020, n = 8; for GluK4 knockout mice F = 0.8476, p = 0.4426, n = 8; Figure
4.2a). On day 2, mice were presented with either the context stimulus, or the
cued stimulus in an altered context, both without the US. There were no
significant differences in freezing between genotypes for the context stimulus
paradigm (Two-way ANOVA, effect of genotype: F = 0.35, p = 0.5625; Figure
4.2b) or the cued stimulus paradigm (Two-way ANOVA, effect of genotype: F =
0.34, p = 0.5701; Figure 4.2c).

Because GluK4 shows limited expression in the dorsal root ganglia of nociceptive
spinal afferent neurons (Lucifora et al., 2006), I performed an incremental hotplate test to investigate the possibility that wild-type and GluK4 knockout animals
had different pain thresholds and were therefore differentially sensitive to the
footshock. Mice were tested in a hot-plate apparatus that increased in
temperature at a rate of 2.5˚C/minute from 43˚ to 57˚C, and no difference in paw
withdrawal latency was observed between genotypes (wild-type, n = 3; GluK4
knockout, n = 5; Student’s T-test, p = 0.3555; Figure 4.2d) indicating that there
was no difference in basal pain threshold between genotypes. Taken together,
these data suggest that, while fear memory storage and retrieval are intact in
GluK4 knockout mice, fear memory acquisition is significantly impaired.
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FIGURE 4.2. GluK4 knockout mice show impaired fear memory acquisition,
but not recall. (A) Freezing behavior increased progressively in the wild-type
cohort (n = 8) after successive tone-shock pairings on day 1 (p = 0.0020), but not
in the GluK4 knockout cohort (n = 8). These findings suggest that GluK4 mice
have impaired fear memory acquisition. (B) Freezing behavior was not
significantly different between genotypes over the course of the context stimulus
trial on day 2 (p = 0.5625). (C) Freezing behavior was not significantly different
during the pre-tone or tone periods of the cued stimulus trial on day 2 (p =
0.5701). Fear memory recall was therefore intact in GluK4 knockout mice. (D)
Wild-type and GluK4 knockout mice did not differ in their latency to withdraw their
paws from an incremental hot plate, indicating that they do not have different
basal pain thresholds. Bars represent mean ± SEM.
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Spatial Learning and Memory are Impaired in GluK4 Knockout Mice
Spatial memory, like fear memory, is also dependent in part on the CA3 region of
the hippocampus: reversible inhibition of mossy fiber transmission results in
impaired spatial memory acquisition in the MWM test of spatial reference
memory (Florian and Roullet, 2004). Thus, I tested wild-type and GluK4 knockout
mice in the MWM to assess whether GluK4 ablation results in spatial memory
deficits.

Mice were initially tested in a visual platform paradigm, where the platform was
raised above the water surface, and no basal differences in visual or swimming
abilities were observed between the genotypes (wild-type n = 13; GluK4
knockout n = 12; two-way ANOVA for latency to reach platform, effect of
genotype, F= 1.15, p = 0.2946; Figure 4.3a).

Mice were then trained for 4 days in a hidden platform paradigm, where the
platform was submerged below the water level, and, thus, no longer visible to the
mice, such that they had to navigate to the platform location using distal spatial
cues. Throughout hidden platform testing the GluK4 knockout cohort performed
significantly worse than the wild-type cohort, demonstrating increased path
length between the point of water entry and the escape platform (Student’s Ttest, p = 0.0231, Figure 4.3b) without any concomitant changes in velocity
(Student’s T-test, p = 0.2407; Figure 4.3c).
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FIGURE 4.3. MWM performance is impaired in GluK4 knockout mice during
hidden platform trials. (A) The latency to reach the platform during the trials
when the platform was visible above the waterline did not differ between wildtype (n = 13) and GluK4 knockout mice (n = 12; p = 0.2946), indicating that
vision, swimming ability, and motivation to escape the water were all equal
between genotypes. (B) Pathlength to reach the hidden platform was increased
in GluK4 knockout mice relative to wild-type mice over the course of the hidden
platform trials (p = 0.0231), indicating that spatial memory is impaired in GluK4
knockout mice. (C) There was no difference between genotypes in swimming
velocity (p = 0.2407), suggesting that the increase in pathlength observed in the
GluK4 knockout mice was not an artifact of hyperactivity. Bars represent mean ±
SEM. VP, visual platform.
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To parse the discrepancies in hidden platform performance between wild-type
and GluK4 knockout mice, I compared the search strategies that they used to
locate the platform based on the schema elaborated by Brody and Holtzman
(Brody and Holtzman, 2006). Search strategies were classified as follows: spatial
strategies, where mice swam directly to the escape platform or to the area
surrounding the platform and searched intently in that region; non-spatial
systematic strategies, where mice did not swim directly to the platform but
instead scanned the pool without spatial bias until they found the platform; and
strategies based on repetitive looping, where mice swam circularly at a fixed
distance from the pool walls without spatial bias (Figure 4.4).

Both wild-type and knockout mice favored non-spatial systematic strategies on
day 1 of the hidden platform trials, presumably because they had not yet learned
the position of the platform (Figure 4.5c). Wild-type mice decreased their reliance
on non-spatial systematic strategies over time in favor of spatial strategies, and
by day 4 they employed spatial search strategies almost exclusively (Figure 4.5df). However, while GluK4 knockout mice also decreased their reliance on nonspatial strategies to some extent, they employed non-spatial systematic
strategies more frequently than wild-type mice by day 3, and this difference
became very robust by day 4 (Chi-square test for overall difference in search
strategy between genotypes, day 3 p = 0.021; day 4 p = 0.001; Figure 4.5e,f).
These findings suggest that the increased path length demonstrated by the
GluK4 cohort in the hidden platform test relative to the wild-type cohort is a
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function of impaired spatial memory acquisition. While wild-type mice learned to
use spatial search strategies over time, GluK4 knockout mice continued to use
non-spatial search strategies to locate the platform.
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FIGURE 4.4. Schematic of search strategies employed by mice in the MWM.
Search strategies were classified as spatial direct (A), non-spatial systematic (B),
or repetitive looping (C) as a measure of MWM performance and, hence, of
spatial learning and memory.
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FIGURE 4.5. GluK4 knockout mice use less efficient search strategies than
wild-type mice to locate the hidden platform in the MWM. Representative
search strategies are shown from wild-type (A) and GluK4 knockout mice (B) to
locate the hidden platform. (C, D) Wild-type (n = 13) and GluK4 knockout mice (n
= 12) both employed non-spatial systematic strategies on day 1 of the hidden
platform trials. (E, F) Wild-type mice decreased their reliance on non-spatial
systematic strategies in favor of spatial strategies to locate the hidden platform
over the course of the trials, while GluK4 knockout mice continued to employ
non-spatial systematic strategies. The overall difference in search strategy
between wild-type and GluK4 knockout search strategy was significant on days 3
and 4 (p = 0.021; p = 0.001, respectively).
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To further assess the role of GluK4 in spatial memory, I performed a probe trial
following hidden platform training in which the escape platform was removed
from the pool altogether. Animals that have learned to navigate to the platform
should spend more time in the quadrant of the pool (target quadrant) in which the
platform was previously located during the hidden platform trials than in the other
quadrants of the pool. A two-way ANOVA with Bonferroni post-hoc analysis for
time spent in each quadrant revealed a significant effect of quadrant (F = 25.63,
p < 0.0001), with a significant difference between genotypes in the time spent in
the target quadrant (p < 0.05), indicating that GluK4 knockout mice showed
decreased preference for the target quadrant when compared with knockout
mice (Figure 4.6).

69

FIGURE 4.6. MWM probe trial performance is impaired in GluK4 knockout
mice. Wild-type (n = 13) and GluK4 knockout mice (n = 12) differed significantly
in their preference for the target quadrant, Q2 (p < 0.05), suggesting that GluK4
knockout mice had not learned the location of the hidden platform and, thus, had
impaired spatial memory recall. Bars represent mean ± SEM. Q1-4, quadrant 14.
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It is possible that the impaired probe trial performance in the GluK4 knockout
cohort is an effect of impaired spatial memory acquisition, as in the hidden
platform trials. It is also possible that this impairment stems from the combined
effects of impaired spatial memory acquisition, consolidation, and/or recall.
Because memory acquisition is impaired in these mice, and memory acquisition
precedes memory consolidation and recall, it is difficult to disambiguate the
individual contributions of each phase of memory formation to the memory
deficits induced by GluK4 ablation. Nevertheless, these experiments highlight the
key role of GluK4 in spatial memory.
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CHAPTER 5: GLUK4 IN MOOD AND NEUROPSYCHIATRIC DISORDERS
Based on associational studies in humans implicating GluK4 in bipolar disorder
and schizophrenia (Pickard et al., 2006; 2008), as well as a concurrent
behavioral study in which GluK2 knockout animals were shown to be less
anxious, more risk-taking, and less despairing than wild-type animals (Shaltiel et
al., 2008), I sought to investigate the behavioral phenotype of GluK4 knockout
animals.

GluK4 Knockout Mice Display Reduced Despair in the Forced Swim Test
First, I performed a forced swim test to assess depressive behavior in wild-type
versus GluK4-deficient animals. Each mouse was placed in beaker of water from
which it was unable to escape, and its mobility over time was recorded and
scored. Immobility in this task is widely considered to be a manifestation of
despair (Porsolt et al., 1977). I found that knockout mice spent less time
immobile over the course of the trial (wild-type mean percent time spent immobile
± SEM = 41.55 ± 2.88%, n = 6; knockout mean percent time spent immobile ±
SEM = 20.82 ± 6.73% n = 5; Student’s T-test, p = 0.0145). A two-way ANOVA of
mobility scored in 1-minute time bins revealed that genotype, time, and the
interaction of genotype and time were all significant (F = 9.29, p = 0.0138; F =
13.34, p < 0.0001; and F = 3.46, p = 0.0100, respectively; Figure 5.1). These
results are again consistent with those observed in GluK2 knockout mice, and,
moreover, suggest that GluK4 may play a modulatory role in baseline affect and
mood.
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FIGURE 5.1. GluK4 knockout mice show decreased despair-type
manifestations in forced swim test. GluK4 knockout mice (n = 5) were
consistently more mobile than wild-type mice (n = 6) over the course of a 6minute forced swim test (p = 0.0138). Bars represent mean ± SEM. * p < 0.05.
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GluK4 Knockout Mice Demonstrate Reduced Anxiety, But Increased Locomotion,
in the Open Field Test
To assess anxiety and risk-taking behavior, wild-type and GluK4 knockout
animals were observed in an open field test. In this task, mice are allowed to
freely investigate an open, evenly lit field, and typically demonstrate robust
thigmotaxis. I found that, while both wild-type and GluK4 knockout mice preferred
the periphery to the center of the field, knockout mice spent proportionally more
time in the center than wild-type mice did (wild-type, n = 13; GluK4 knockout, n =
12; Student’s T-test, p = 0.007, Figure 5.2a). Knockout mice also entered the
center more frequently than wild-type mice (Student’s T-test, p = 0.004; Figure
5.2b).

Additionally, knockout mice showed marked hyperactivity relative to the wild-type
mice in the open field. The knockout mice traveled greater total distances
(Student’s T-test, p = 0.0004; Figure 5.2c) over the course of the assay at higher
average velocities than wild-type mice (wild-type mean velocity in cm/second ±
SEM = 6.92 ± 0.42; knockout mean velocity in cm/second ± SEM = 9.75 ± 0.54;
Student’s T-test, p = 0.0004).
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FIGURE 5.2. GluK4 knockout mice show decreased aversion to center
zone, and increased locomotion in short / lit open field. (A) Though both
wild-type (n = 13) and GluK4 knockout mice (n = 12) preferred the periphery to
the center zone of the open field during a 5-minute trial, the GluK4 knockout mice
spent proportionally more time in the center zone of the open field (and, thus,
proportionally less time in the periphery of the open field) than wild-type mice (p =
0.007), suggesting that GluK4 knockout mice have decreased basal levels of
anxiety relative to wild-type mice. (B) GluK4 knockout mice entered the center
zone more frequently than wild-type mice over the course of the trial (p = 0.004).
(C) GluK4 knockout mice traveled greater distances over the course of the trial
than wild-type mice, suggesting that GluK4 knockout mice may be hyperactive (p
= 0.0004). Bars represent mean ± SEM.

75

76

Because hyperactivity could confound the interpretation of the differences
between wild-type and GluK4 knockout mice in center zone preference and
center zone entries, making it difficult to disambiguate the relative contributions
of anxiety and locomotion, I tested separate cohorts of wild-type and GluK4
knockout mice in a second open field paradigm where the primary anxiogenic
stimulus – light – was removed. The observation period was also extended to an
hour to assess whether mice habituated to the open field environment. Thus, in
this second paradigm (long / dark), I investigated whether hyperlocomotion was a
function of anxiety or the novelty of the open field environment, rather than a
constant feature of GluK4 knockout mouse behavior.

I found that the distance traveled by wild-type and GluK4 knockout mice
decreased over time as the mice habituated to the environment. However, GluK4
knockout mice consistently traveled greater distances throughout the 1-hour
observation period than wild-type mice, despite demonstrating habituation (Twoway ANOVA: effect of genotype, F = 8.435, p = 0.0076; effect of time, F = 31.26,
p < 0.0001; wild-type n = 15, knockout n = 12; Figure 5.3a). Hyperlocomotion in
GluK4 knockout animals was therefore independent of the novelty of the
environment.

The number of center entries per time bin decreases progressively throughout
the trial, in a similar fashion to total distance traveled. However, a two-way
ANOVA revealed that the number of center entries in the GluK4 knockout cohort
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is significantly higher than in the wild-type cohort (effect of genotype, F = 5.42, p
= 0.0283; Figure 5.3b). Meanwhile, GluK4 mice appeared to spend more time in
the center zone than wild-type mice, though the data for each time point were
variable, and the difference was not quite significant by two-way ANOVA (effect
of genotype, F = 4.00, p = 0.0564; Figure 5.3c). There was also a significant
effect of time on the percent of time spent in the center zone: both wild-type and
GluK4 knockout animals appear to have spent more time in the center zone as
the trial progressed (F = 3.47, p = 0.0002).
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FIGURE 5.3. GluK4 mice show decreased aversion to center zone, and
increased locomotion in long / dark open field. (A) The distance traveled by
GluK4 knockout mice (n = 12) was consistently greater than that traveled by wildtype mice (n = 15; p = 0.0076). Nevertheless, both wild-type and GluK4 knockout
cohorts habituate to the open field environment over the course of the 1-hour
trial. (B) The frequency of center zone entry is greater in GluK4 knockout mice
than in wild-type mice (0.0283). (C) The proportion of time spent in the center
zone is different, though not quite significantly (p = 0.0564), between wild-type
and GluK4 knockout mice over the course of the trial. Bars represent mean ±
SEM.
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Together, these results suggest several interpretations. One possibility is that
hyperlocomotion accounts for the differences in center entries and percent time
spent in center in both the first (short / lit) and the second (long / dark) open field
paradigms, and that there is no difference in basal anxiety levels between wildtype and GluK4 knockout mice. Another possibility is that in the first paradigm, it
is the open area of the field itself that is serving as the primary anxiogenic
stimulus, independently of the ambient illumination. Thus, the fact that wild-type
and GluK4 knockout mice differed in center zone preference in both the first and
second paradigms could still be attributed to basal differences in anxiety. This
would also explain why the time spent in the center zone in the second paradigm
increased in both wild-type and knockout cohorts: as they became more familiar
with the environment, the center zone may have become less anxiogenic.

GluK4 Ablation Affects PPI and the Acoustic Startle Response
PPI is a cross-species indicator of sensorimotor gating, and involves a
suppression of the startle response evoked by a loud tone when that tone is
immediately preceded by a weaker tone (Geyer et al., 1990). Under normal
conditions, PPI is thought to be a precognitive means of preventing sensory
overload (van den Buuse, 2010). Meanwhile, impaired PPI is widely considered
to be an endophenotype of schizophrenia – a disorder characterized by cognitive
disorganization and an inability to distinguish between salient and non-salient
environmental cues (Perry and Braff, 1994). The cellular basis of PPI is complex
and involves many brain structures and neurotransmitter systems, among which
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are the hippocampus and glutamate, respectively (Reijmers et al., 1995; Koch,
1996).

To assess the effect of GluK4 ablation on PPI, I evaluated wild-type and GluK4
knockout mice in a multi-block PPI paradigm. First, the startle response to single
pulses with intensities ranging from 80 – 120 dB was analyzed. Next, the pulse
was preceded by a prepulse, and the pulse intensity was maintained at 120 dB,
while the prepulse intensity was varied from 3 to 12 dB above the background
white noise level of 65 dB. Finally, the prepulse and pulse were maintained at 6
dB (above background) and 120 dB, respectively, and the ISI between the
prepulse and the pulse was varied from 25 to 500 milliseconds.

The overall response to single acoustic pulses of varying intensity was
significantly different between wild-type and GluK4 knockout mice (two-way
ANOVA, effect of genotype, F = 7.12, p = 0.0132; wild type n = 15, knockout n =
12; Figure 5.4a). Post-hoc analysis of the individual pulse intensities revealed
that the response to 80, 90, and 100 dB pulses was largely the same between
genotypes, but that GluK4 knockout mice displayed significantly reduced startle
intensities relative to wild-type mice at 110 dB (p < 0.01) and 120 dB (p <
0.0001).

PPI was measured as a percentage, representing the ratio of the magnitude of
the startle response (Vmax) evoked by a pulse following a prepulse, over the
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magnitude of the average baseline startle response to a single 120 dB pulse.
Overall, the percent PPI was also significantly reduced in GluK4 knockout mice
compared to wild-type mice (two-way ANOVA, effect of genotype, F = 8.52, p =
0.0073; Figure 5.4b), indicating that GluK4 mice do not effectively inhibit the
startle response following a prepulse. Post-hoc analysis indicated that this effect
was significant at a prepulse intensity of 6 dB (p < 0.01) and 12 dB (p < 0.001)
above background. Varying the ISI between the prepulse and the pulse did not
yield a significant difference between wild-type and GluK4 knockout mice (twoway ANOVA, effect of genotype, F = 2.34, p = 0.1387; Figure 5.4c).

83

FIGURE 5.4. The acoustic startle response and PPI are impaired in GluK4
knockout mice. (A) GluK4 knockout mice (n = 15) showed a decreased reaction
relative to wild-type mice (n = 12) to acoustic pulses of varying intensity (p =
0.0132). (B) %PPI was decreased in GluK4 knockout mice (p = 0.0073),
suggesting impaired sensorimotor gating. (C) Varying the ISI did not result in
significant differences in %PPI between wild-type and GluK4 knockout mice (p =
0.1387). Bars represent mean ± SEM. ** p < 0.01, *** p < 0.001
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Taken together, these results indicate that GluK4 knockout mice show deficits in
PPI, as well as the acoustic startle response to a single pulse. The deficit in PPI
indicates that GluK4 plays an essential role in sensorimotor gating, and
reinforces the hypothesis that impaired GluK4 function or expression contributes
to the pathogenesis of schizophrenia. Furthermore, the deficit in the acoustic
startle response observed in GluK4 knockout mice suggests a more general
difference in emotionality and arousal between wild-type and knockout mice, as
the acoustic startle response is modulated by corticotropin releasing factor, a
hormone that has been implicated in anxiety disorder and major depression
(Risbrough et al., 2003). Thus, the deficit in the acoustic startle response
dovetails with the decreased anxiety- and depressive-like behaviors in GluK4
knockout mice that I observed in the open field test and forced swim test,
respectively.
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CHAPTER 6: GLUK4 IN EXCITOTOXIC NEURODEGENERATION
GluK4 Mediates Kainate-induced Neurodegeneration in the CA3 Region of the
Hippocampus
The hippocampus as a whole, and the CA3 region in particular, is exceptionally
vulnerable to excitotoxic neurodegeneration due to its high concentration of
ionotropic glutamate receptors (Nadler, 1981; Ben-Ari, 1985). The CA3 also
corresponds to the region of highest GluK4 expression within the brain (Darstein
et al., 2003). To determine the effect of GluK4 deficiency on excitotoxicity, I
performed IH stereotaxic kainate injections on wild-type and GluK4 knockout
animals. 24 hours after surgery, animals were perfused with saline and PFA, and
their brains were removed and sliced on a microtome. Staining the resulting
sections with FJC, a marker of degenerating neurons (Schmued et al., 2005),
revealed that kainate resulted in extensive cell death in the CA1, CA3, and hilar
regions of the hippocampus in wild-type animals (Figure 6.1a, b). However, the
CA3 region appeared to be largely spared in GluK4 knockout animals (Figure
6.1e, f). Because it was possible that the lack of FJC staining in the CA3 region
of GluK4 knockout sections was actually the result of cell death so severe that
the cells in that region had already been degraded, I co-stained the sections with
DAPI to assess the general morphology and integrity of the remaining cells. In
GluK4 knockout tissue, cells within the CA3 region appeared to be intact and
densely packed, while in wild-type tissue, they appeared to be pyknotic and
sparsely distributed (Figure 6.1c, d, g, h). Thus, the CA3 region was indeed
neuroprotected following kainate injection in GluK4 knockout animals.
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I then used stereological methods to quantify the density of FJC staining, and
thereby compare the relative extent of neurodegeneration in wild-type versus
GluK4 knockout hippocampal tissue. As I had observed in my preliminary
investigations, I found that GluK4 deficiency resulted in significantly reduced
kainate-induced cell death in the CA3 region (Student’s T-test, p = 0.0271), but
not in the CA1, CA2, or dentate gyrus (Figure 6.1i). These results indicate that
GluK4 activation is primarily responsible for excitotoxic cell death within the CA3.
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FIGURE 6.1. GluK4 ablation attenuates kainate-induced neurodegeneration
in the CA3. FJC- (A, B) and DAPI- (C, D) stained tissue from of KA-treated wildtype animals revealed neurodegeneration throughout the hippocampus. (B) and
(D) correspond to enlargements of the indicated regions of (A) and (C),
respectively, and demonstrate extensive neurodegeneration in the CA3 region of
the hippocampus. FJC- (E, F) and DAPI- (G, H) stained tissue from KA-treated
GluK4 knockout animals revealed decreased neurodegeneration relative to wildtype animals, specifically in the CA3 region of the hippocampus (F, H) where
GluK4 expression is most concentrated. (F) and (H) represent enlargements of
indicated regions of (E) and (G), respectively. (I) Stereological quantification of
neurodegeneration, corresponding to mean area of FJC staining, demonstrated
specific neuroprotection of the CA3 region in GluK4 knockouts (p = 0.0271). Bars
represent mean ± SEM.
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FIGURE
6.2.
GluK4
ablation
attenuates
ischemia-induced
neurodegeneration throughout the hippocampus. HI resulted in extensive
neurodegeneration throughout the hippocampus of wild-type animals as
indicated by FJC (A) and DAPI (B) staining. FJC staining for neurodegeneration
(C) was strongly reduced in GluK4 knockout animals, and DAPI staining (D)
showed intact cells throughout all subregions of the hippocampus. (E)
Stereological quantification of neurodegeneration reflects neuroprotection
throughout the hippocampus in GluK4 knockout animals relative to wild-type
animals after HI (p = 0.0405), particularly in the CA1 (p = 0.0371), CA2 (p =
0.0187), and CA3 (p = 0.0189) subregions. Bars represent mean ± SEM.
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GluK4 Orchestrates Widespread Hippocampal Neurodegeneration Following HI
To further explore the role of GluK4 in neurodegeneration in a clinically relevant
context, Anna Kruyer, a fellow student in my laboratory with whom I worked
closely on many of the experiments described herein, compared
neurodegeneration in wild-type and GluK4 knockout mice following transientglobal ischemia (HI), a murine model of stroke. Mice were subjected to unilateral
transection of the left common carotid artery, followed by 45 minutes of hypoxia.
Using the same stereological methods to assess cell death as in the stereotaxic
kainate injections described above, Anna found that HI resulted in extensive cell
death in all hippocampal subregions. However, GluK4-deficient animals showed
dramatically reduced neurodegeneration throughout the hippocampus relative to
wild-type animals (Student’s T-test, p = 0.0405), particularly in the CA1
(Student’s T-test, p = 0.0371), CA2 (Student’s T-Test, p = 0.0187) and CA3
subregions (Student’s T-Test, p = 0.0189) (Figure 6.2). The robust
neuroprotection afforded by GluK4 ablation suggests that GluK4 plays a role in
initiating the molecular cascades that lead to neurodegenerative cell death.
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CHAPTER 7: MOLECULAR MECHANISMS OF GLUK4-MEDIATED
NEURODEGENERATION
The neuroprotection observed in GluK4 knockout mice following administration of
kainate or HI suggested that GluK4 was critical to the activation of cell death
pathways. To elucidate the role of GluK4 in the molecular cascades leading to
neurodegeneration, I designed a microarray assay in which I compared mRNA
expression levels from kainate- versus PBS-injected wild-type and knockout
samples. Enriched genes were further analyzed to extrapolate enriched
molecular pathways. I chose to employ the kainate-mediated model of
neurodegeneration over the HI-mediated model because the nature of the insult
– kainate – is specific to kainate receptors and the extent of damage is highly
reproducible between animals.

Microarray Design
Using the same IH injection protocol as I had to perform the stereology
experiments described above, I bilaterally injected wild-type and GluK4 knockout
mice with kainate or PBS. 24 hours after injection, hippocampi from both
hemispheres were isolated, and one from each animal was further
microdissected to isolate the CA3, as the neuroprotective effect of GluK4 ablation
is restricted to the CA3 in the kainate-mediated model of neurodegeneration.
However, the CA3 region is difficult to isolate and yields far less mRNA than
whole hippocampus samples. To preclude the possibility that the CA3 samples
might under-represent the molecular changes induced by kainate injection by
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yielding insufficient or poor-quality mRNA, I included both CA3 and whole
hippocampus samples in the microarray design. In sum, I tested the effects of
treatment (kainate versus PBS), genotype (wild-type versus GluK4 knockout),
and tissue (whole hippocampus versus CA3). All conditions included in the
microarray are outlined in Table 7.1.

TABLE 7.1. Microarray conditions.
Genotype
Wild-type
Wild-type
GluK4 Knockout
GluK4 Knockout
Wild-type
Wild-type
GluK4 Knockout
GluK4 Knockout

Injection
PBS
PBS
PBS
PBS
Kainate
Kainate
Kainate
Kainate

Tissue Type
Whole hippocampus
CA3
Whole hippocampus
CA3
Whole hippocampus
CA3
Whole hippocampus
CA3

Microarray Sample Quality Control
All RNA samples were purified after extraction, and bioanalyzed to assess the
RNA integrity number (RIN) of each sample. Any samples where the RIN fell
below 8 were re-purified.

To ensure that CA3 samples were free, or as free as possible, of contamination
from neighboring subregions, I performed one-step RT-PCR on CA3 mRNA
samples using primers that were designed to amplify Nov and Dsp, genes
specific to the CA1 and DG subregions, respectively. Reactions for each regionspecific primer set were optimized for cycle number and RNA concentration.
PCR products were then analyzed semi-quantitatively for Nov and Dsp levels,
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and samples that yielded the lowest expression of each – i.e., were least
contaminated – were selected for further experiments (Figures 7.1 and 7.2).
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FIGURE 7.1. Assessing contamination of microarray CA3 samples by DG
tissue. (A) Representative gels of one-step RT-PCR assays for the DG marker
Dsp show varying levels of DG contamination in CA3 samples. A DG sample was
run as a positive control in the last lane. (B) Semiquantitative analysis of Dsp
expression was used to select the least-contaminated CA3 samples from each
condition. KA, kainate-injected samples; PBS, PBS-injected samples; + control,
pure DG mRNA used as template instead of CA3 mRNA.

96

FIGURE 7.2. Assessing contamination of microarray CA3 samples by CA1
tissue. (A) Representative gels of one-step RT-PCR assays for the CA1 marker
Nov show varying levels of CA1 contamination in CA3 samples. A CA1 sample
was run as a positive control in the last lane. (B) Semiquantitative analysis of
Nov expression was used to select the least-contaminated CA3 samples from
each condition. + control, pure CA1 mRNA used as template instead of CA3
mRNA.
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Additionally, all CA3 and whole hippocampus samples were analyzed to
determine whether the samples that were supposed to receive kainate had
actually received it. FJC staining of kainate-injected tissue will occasionally
reveal that kainate has not been properly administered, perhaps as a result of air
bubbles in the injection syringe or defects in the injection pump. Thus, expression
levels of Hsp27, a heat shock protein that has been shown to be highly upregulated following IP kainate injection (Brecht et al., 2005), were assessed by
one-step RT-PCR as a positive indicator of kainate injection. Hsp27 has the
added advantage of being neuroprotective in excitotoxic conditions, as
transgenic mice that overexpress Hsp27 are neuroprotected in the context of
MCAO, indicating that it may still be up-regulated in GluK4 CA3 samples despite
resistance of cells in that region to kainate-induced neurodegeneration. Hsp27
was indeed observed in both kainate-injected wild-type and GluK4 knockout
tissue, and expression levels were indistinguishable using semi-quantitative
analysis (Figure 7.3). Ultimately, all kainate-injected samples had received
kainate.
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FIGURE 7.3. Assessing Hsp27 expression as a measure of successful
kainate injection. (A) Levels of Hsp27, a neuroprotective gene that is highly upregulated in the context of excitotoxicity, were assessed in kainate- and PBSinjected samples using one-step RT-PCR. Kainate- and PBS-injected samples
were interspersed in these gels, with the exception of the last gel in which only
kainate-injected samples were run. (B) Semiquantitative analysis revealed that
all samples that were supposed to receive kainate had actually received it.
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Three samples from each of the eight conditions outlined in Table 7.1 were
pooled and submitted to the Genomics Core Facility at The Rockefeller
University, where they were then labeled, hybridized to the individual wells of an
Illumina Expression BeadChip, and scanned. Raw gene expression signals were
thresholded as described in materials and methods.

Gene Enrichment in CA3 Versus Whole Hippocampus Samples
For all conditions examined, whole hippocampus samples yielded fewer enriched
genes than CA3 samples. For instance, the list of genes up-regulated by 2-fold or
greater in wild-type CA3 tissue following kainate injection included 559 genes,
while the same list in whole hippocampus tissue included only 336 genes. One
reason for this difference may be that CA3-specific changes in gene regulation
were counterbalanced by a lack of change, or perhaps changes in the opposite
direction, in the same genes in other regions of the hippocampus. Thus, whole
hippocampus samples were excluded from further analysis, and all of the results
reported here are from CA3 samples.

Gene Enrichment Following Kainate Injection in Wild-type Versus GluK4
Knockout Samples
To determine the effects of kainate on gene expression, the fold-change in gene
expression levels in the kainate condition relative to the PBS condition was
calculated for each genotype. The resulting wild-type and GluK4 knockout gene
lists were then compared to determine the effects of kainate on gene expression
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between genotypes. Only genes with a fold-change greater than |2| in the kainate
condition relative to the PBS condition for each genotype were included in this
analysis. 3 gene lists emerged: genes that were exclusively up-regulated in wildtype tissue, i.e., up-regulated by 2-fold or more in wild-type tissue but not GluK4
knockout tissue following kainate injection, relative to PBS (320 genes
altogether); genes that were exclusively up-regulated in GluK4 knockout tissue
(74 genes); and genes that were up-regulated in both wild-type and GluK4
knockout tissue (239 genes) (Figure 7.4). The top 30 genes in the wild-typeexclusive and GluK4 knockout-exclusive lists are outlined in Tables 7.2 and 7.3.
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FIGURE 7.4. Schematic Venn diagram of gene enrichment in wild-type
versus GluK4 knockout samples after kainate injection. 320 genes were
exclusively enriched by |2|-fold or more following kainate injection (relative to
PBS injection) in wild-type samples (orange); 74 genes were exclusively enriched
in GluK4 knockout samples (blue); and 239 genes were enriched in both.
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TABLE 7.2. Genes enriched in wild-type samples following kainate.
Gene Name

Symbol

Fold-change in wildtype following
kainate, relative to
PBS

β-actin

Actb

-50.522327

-1.2285179

growth hormone

Gh

17.440138

1.1244828

prolactin

Prl

7.5980372

-1.0499934

purkinje cell protein 2 (L7)

Pcp2

6.7068973

1.4683733

solute carrier family 13 (sodium/sulfate
symporters), member 4

Slc13a4

6.142569

-1.9992677

sulfatase 1

Sulf1

5.927293

-1.0554414

prolactin receptor

Prlr

5.5717325

-1.3291636

decorin

Dcn

5.001785

1.7570093

matrix Gla protein

Mgp

4.4215

1.5079937

retinol dehydrogenase 5

Rdh5

4.349441

-1.2431543

insulin-like growth factor 2

Igf2

4.2631984

-1.9494125

insulin-like growth factor binding protein 2

Igfbp2

4.242587

-1.1547633

nuclear receptor co-repressor 1
solute carrier family 17 (sodium-dependent
inorganic phosphate cotransporter), member
6
lectin, galactose binding, soluble 1

Ncor1

-4.0182915

1.1821797

Slc17a6

4.0027905

1.4765645

Lgals1

3.896389

1.9174436

gap junction protein, β-2

Gjb2

3.4975474

1.3912534

interferon-induced protein with
tetratricopeptide repeats 3

Ifit3

3.49664

1.3959935

interferon, α-inducible protein 27

Ifi27

3.4579968

1.1008872

tubulin, α-1c

Tuba6

3.4517848

1.6111073

rap guanine nucleotide exchange factor
(GEF)-like 1

Rapgefl1

-3.4238975

-1.9603293

tubulin, β-2b

Tubb2b

3.2463224

1.39096

LOC100045241

-3.2053182

-1.5128021

Lgals3bp

3.2032213

1.2697843

LOC100048346

3.1747127

1.701681

chemokine (C-C motif) ligand 2

Ccl2

3.154905

1.9624745

protein kinase C, γ

Prkcc

-3.1515055

-1.9287628

Hspd1

3.1073248

1.2092633

LOC667370

3.1015675

1.7340547

Vat1l

3.0500953

-1.2528175

Hnrnpa2b1

3.043459

1.1359648

leucine rich repeat containing 4B; similar to
Leucine rich repeat containing 4B
lectin, galactoside-binding, soluble, 3 binding
protein
ubiquitin specific peptidase 18; similar to
ubiquitin specific protease UBP43

predicted gene 12141; heat shock protein 1
(chaperonin)
I830012O16Rik RIKEN cDNA I830012O16
gene
vesicle amine transport protein 1 homolog-like
(T. californica)
predicted gene 5778; similar to
heterogeneous nuclear ribonucleoprotein
A2/B1; heterogeneous nuclear
ribonucleoprotein A2/B1
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Fold-change in
knockout following
kainate, relative to
PBS

TABLE 7.3. Genes enriched in GluK4 knockout samples following kainate

Gene Name

Symbol

Fold-change in
knockout following
kainate, relative to PBS

Fold-change in wildtype following kainate,
relative to PBS

similar to α-lactalbumin; lactalbumin, α

Lalba

3.6236696

1.1536819

sclerostin domain containing 1

Sostdc1

-3.3527162

1.4620374

inositol 1,4,5-trisphosphate 3-kinase A

Itpka

-3.2814567

-1.9674851

glycine dehydrogenase

Gldc

-3.1782527

-1.9073267

acyl-CoA thioesterase 11

Acot11

-3.0526004

-1.673179

tyrosinase-related protein 1

Tyrp1

3.0267994

1.3415347

cysteine and glycine-rich protein 3

Csrp3

3.000433

1.3494827

Ca2+-dependent activator protein for
secretion 2

Cadps2

-2.7261322

-1.7462686

fibrinogen C domain containing 1

Fibcd1

-2.6653936

-1.2815868

pleckstrin and Sec7 domain containing 2

Psd2

-2.6561596

-1.3567331

chromagranin A

Chga

2.6017258

1.8398476

B-cell linker

Blnk

2.5908782

1.6979231

glycine decarboxylase

Gldc

-2.5458357

-1.817069

sulfotransferase family 1A, phenol-preferring,
member 1

Sult1a1

-2.5454924

-1.2607372

serine peptidase inhibitor, Kazal type 8

Spink8

-2.520413

-1.592723

similar to calponin 3, acidic; predicted gene
4815; calponin 3, acidic

LOC1000478
56

2.508167

1.8010483

strawberry notch homolog 2 (Drosophila)

Sbno2

2.5037324

1.9636917

solute carrier family 7 (cationic amino acid
transporter, ψ+ system), member 10

Slc7a10

-2.4803817

-1.3164182

polymerase (DNA-directed), δ 4

Pold4

2.44297

1.8516624

multiple EGF-like-domains 11

Megf11

2.4371126

1.8443365

glucosaminyl (N-acetyl) transferase 2, Ibranching enzyme

Gcnt2

2.425731

1.7545487

lin-7 homolog B (C. elegans)

Lin7b

-2.39229

-1.9965154

activin A receptor, type IC

Acvr1c

2.3459048

1.6499034

phosphoatidic acid phosphatase type 2B

Ppap2b

-2.3409045

-1.7861793

ST6 (α-N-acetyl-neuraminyl-2,3-β-galactosyl1,3)-N-acetylgalactosaminide a-2,6sialyltransferase 4

St6galnac4

2.3217778

1.772647

chromogranin A

Chga

2.3211932

1.7686646

solute carrier family 39 member 12

Slc39a12

-2.3190215

-1.4546387

VGF nerve growth factor inducible

Vgf

2.3179793

1.6363449

B-cell leukemia/lymphoma 3

Bcl3

2.3033428

1.9761575

interferon γ induced GTPase

Igtp

2.2822418

1.8902932
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DAVID Analysis of Enriched Molecular Pathways Indicates Enrichment of the
JNK Pathway in Kainate-treated Wild-type Samples
The list of genes exclusively up-regulated following kainate treatment in wildtype, but not GluK4 knockout tissue, represents the genes that are enriched in a
GluK4-dependent manner. To gain insight into the molecular pathways in which
GluK4 might participate to mediate neurodegeneration, this list was analyzed
using the Database for Annotation, Visualization and Integrated Discovery
(DAVID), a program that compares gene lists against various pathway databases
and extracts statistically over-represented (i.e., enriched) pathways (Huang et al.,
2007).

Using the DAVID program, the list of genes exclusively enriched in wild-type
tissue was compared against the Kyoto Encyclopedia of Genes and Genomes
(KEGG) database. Significantly enriched pathways (p < 0.05) are outlined in
Table 7.4. The biological relevance of some of these pathways, such as the type
II diabetes mellitus pathway, to GluK4-mediated excitotoxicity is not immediately
clear. However, among the significantly enriched pathways, the Mitogen
Activated Protein Kinase (MAPK) signaling pathway is of particular interest: while
it includes many auxiliary pathways and governs diverse physiological
processes, including proliferation, differentiation, and inflammation, it also
mediates apoptosis through the subset of MAPK proteins that comprise the JNK
pathway (Schaeffer and Weber, 1999).
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TABLE 7.4. KEGG pathways exclusively enriched in wild-type samples following
kainate
KEGG Pathway

p Value

Genes

Type II diabetes mellitus

0.0011

GnRH signaling pathway

0.0047

Glycerolipid metabolism

0.0400

MAPK1, HK1, MAPK10, PRKCE, ABCC8, PRKCD
MAPK1, ADCY9, PTK2B, JUN, MAPK10, CAMK2A,
PRKCD
LPL, DGKB, DGKZ, MGLL

Homeostasis/Energy Metabolism

Neurotransmission
Neuroactive ligand-receptor
interaction

0.0030

TSPO, THRA, GRIA2, PRLR, NPY2R, GRIK5, GRIA3,
NPY1R, GRM1, PRL, GH, F2R

Long-term potentiation

0.0053

MAPK1, GRIA2, PPP3R1, GRM1, CAMK2A, PRKCC

Long-term depression

0.0060

MAPK1, GNAO1, GRIA2, GRIA3, GRM1, PRKCC

Gap junction

0.0125

MAPK1, TUBB2B, ADCY9, GRM1, PRKCC, TUBB4

Calcium signaling pathway

0.0346

ADCY9, PTK2B, RYR3, PPP3R1, GRM1, CAMK2A,
PRKCC, F2R

0.0128

KCNMA1, MAPK1, ADCY9, ACTA2, PRKCE, PRKCD,
PRKCC

0.0270

MAPK1, DUSP1, JUN, PPP3R1, FGF10, HSPA1A,
FGF13, MAPK10, PRKCC, HSPA8

0.0473

ICAM1, MAPK1, PTK2B, PPP3R1, FCGR4, PRKCC

Hemovascular function
Vascular smooth muscle contraction
Cell death
MAPK signaling pathway
Immunity
Natural killer cell mediated
cytotoxicity

There is strong evidence to suggest that the JNK pathway mediates excitotoxic
neurodegeneration, as outlined in Chapter 1: mice deficient in JNK3, the
neuronal isoform of JNK, are resistant to neurodegeneration following MCAO and
IP kainate injection (Brecht et al., 2005), and JNK pathway-inhibiting compounds
are neuroprotective (Bogoyevitch et al., 2004). There is also evidence linking
JNK pathway activation and kainate receptors: MLK3, an earlier initiator of the
JNK pathway kinase cascade, can form a complex with GluK2 and PSD95 that
results in MLK3-autophosphorylation and, subsequently, JNK pathway activation
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(Tian et al., 2005; Jiang et al., 2007). These findings, in conjunction with the
enrichment of the MAPK pathway in wild-type but not GluK4 knockout tissue,
suggested that GluK4 might mediate excitotoxic neurodegeneration through the
JNK pathway.

Performing the same DAVID analysis with the list of genes exclusively enriched
in GluK4 knockout tissue after kainate – genes that might play a neuroprotective
role in the context of excitotoxicity – yielded no significantly enriched pathways.

GSEA Analysis Reveals Selective Enrichment of Cell Death Pathways in
Kainate-treated Wild-type Samples
The DAVID program does not take into account the relative enrichment (i.e., foldchange values) of the genes within a given list, merely the gene names, when
extrapolating enriched pathways. While this low stringency can be considered an
advantage in the sense that it facilitates pathway discovery, it is also a
disadvantage in the sense that it may over- or underestimate the importance of a
given pathway by giving weight to the number – rather than the magnitude of
regulation – of genes within a given list that coincide with a given pathway.
Furthermore, DAVID cannot distinguish between significantly up-regulated
versus significantly down-regulated pathways, thereby clouding downstream
interpretations of biological relevance.
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To address these issues, I performed a second round of analysis using GSEA
software. GSEA can incorporate the magnitude – and, to some extent, the
direction – of regulation of the genes within the list to generate a set of proposed
pathways in which those genes might participate (Subramanian et al., 2005).
GSEA was run from two distinct gene lists: all genes probed in the microarray
from 1. wild-type, and 2. GluK4 knockout tissue, ranked by fold-change after
kainate administration relative to their respective PBS baseline. These lists were
then compared against the Biocarta pathway database to assess positively
enriched (up-regulated) and negatively enriched (down-regulated) pathways.

As with DAVID analysis, the set of positively enriched pathways that is exclusive
to the wild-type condition (Table 7.5) gives insight into the molecular actions of
GluK4 downstream of kainate administration. While the relevance of some of the
enriched pathways to GluK4-mediated neurodegeneration is not immediately
apparent (for instance, the erythrocyte pathway), there is a clear enrichment of
cell-death-mediating pathways. These include, in order from most to least
statistically significant, the p53 hypoxia pathway, which involves the induction of
apoptosis through p53; the caspase pathway, which involves the induction of
apoptosis through the caspase proteolytic cascade; the death receptor pathway,
which involves the induction of apoptosis through DR3 and DR4/5 receptors; the
D4-GDI pathway, which involves the induction of apoptosis through D4-GDI, a
molecule that regulates the cytoskeletal changes associated with apoptosis
through the Rho family of GTPases; the Fas pathway, which involves the
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induction of apoptosis through the cell-surface expressed Fas receptor; and the
ceramide pathway, which involves the induction of apoptosis through ceramide, a
lipid signaling molecule.

TABLE 7.5. Biocarta pathways exclusively enriched in wild-type samples
following kainate
Biocarta Pathway
Cell Death
p53 hypoxia Pathway

P Value

Genes (with Core Enrichment)

0.019

CDKN1A, HSP1A1, GADD45A, IGFBP3, CSNK1D

Caspase Pathway

0.019

ARHGDIB, LMNA, LMNB1, CASP8, CASP1, CASP4,
CASP9, LMNB2, BIRC, CASP3, CASP7, CASP2, CASP6,
APAF1, BIRC3, PRF1

Death Receptor Pathway

0.018

LMNA, FADD, CASP8, RELA, MAP3K14, NFKB1,
TNFRSF10B, RIPK1, NFKBIA, TRAF2, CASP9, BIRC4,
CASP3, CASP7, CASP6, APAF1, BIRC3

D4-GDI Pathway
Fas Pathway
Ceramide Pathway
Cell Survival and Proliferation
IGF-1 Pathway
Nerve Growth Factor Pathway
Immunity

0.020
0.058
0.050

not reported by GSEA
not reported by GSEA
not reported by GSEA

0.041
1.627

FOS, JUN, SHC1
not reported by GSEA

Toll-like Receptor Pathway

0.017

FOS, CD14, TLR2, JUN, MAP2K3, MYD88, RELA, TLR7,
TIRAP, MAP3K14, NFKB1, LY96, NFKBIA, TLR4, IRAK1,
TLR6, TRAF6

0.000

CCL4, CCL3, CCR5

0.020
0.051

FOS, STAT, JUN, CEBPB, SHC1
not reported by GSEA

0.034

FOS, JUN, SHC1

0.017

F2R, PROS1, SERPING1, COL4A4, COL4A5, COL4A1,
F5, COL4A2, COL4A6, FGA, FGG, SERPINC1, KLKB1

0.034

not reported by GSEA

Natural Killer T-Cell Polarization
Pathway
IL6 Cytokine Pathway
B Lymphocyte Pathway
Homeostasis/Energy
Metabolism
Insulin Pathway
Hemovascular Function
Intrinsic Prothrombin Activation
Pathway
Erythrocyte Differentiation
Pathway

Amongst the pathways that were positively enriched in the GluK4 knockout
samples (Table 7.6), the EPO NFkB pathway stands out a potential modulator of
cell survival in the CA3. Aside from its role in the production of erythrocytes,
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erythropoietin (EPO) promotes neuroprotection in murine models of stroke by
activating a variety of downstream signaling pathways, including the NFkB
pathway (van der Kooij et al., 2008). This finding suggests that GluK4 may
directly suppress the neuroprotective functions of EPO in the context of kainateinduced excitotoxicity, or, perhaps more plausibly, that pathways downstream of
GluK4 activation modulate EPO production. Establishing the molecular
pathway(s) that lead(s) to the up-regulation of the EPO NFκB following kainate
administration in the absence of GluK4 was outside the scope of this thesis, but
may warrant future investigation.

Very few pathways were negatively enriched either the wild-type or GluK4
knockout samples. Two pathways mediating immunity – the MEF2D pathway,
and the NK Cells pathway – were down-regulated in wild-type samples. In GluK4
samples, down-regulated pathways included the Bad cell death pathway, the
CK1 cell signaling pathway that is involved in dopamine signaling, and the
Glycolysis and Kreb pathways, both of which regulate homeostasis and energy
metabolism. The down-regulation of these pathways leads to many hypothesis
as to their role in GluK4-mediated neurodegeneration. Down-regulation of the
Bad cell death pathway in GluK4 knockout tissue may be of particular interest, as
it parallels the up-regulation of pro-apoptotic pathways in wild-type tissue.
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TABLE 7.6. Biocarta pathways exclusively enriched in GluK4 knockout samples
following kainate
Biocarta Pathway

P Value

Genes (with Core Enrichment)

IMMUNITY
Tcr Pathway

0.051

Not reported by GSEA

Il2 Pathway

0.048

Not reported by GSEA

Tid Pathway

0.053

Not reported by GSEA

Cd40 Pathway

0.037

41bb Pathway

0.019

DUSP 1, NFKBIA, RELA, NFKB1, TRAF6, CHUK, IKBKG,
MAP3K14
JUN, NFKBIA, RELA, MAP4K5, NFKB1, IFNG, TNFSF9,
CHUK, ATF2

CELL SURVIVAL
Rela Pathway

0.000

EPO NFkB Pathway

0.036

TNFRSF1A, NFKBIA, RELA, RIPK1, NFKB1, FADD,
TRAF6, TNF, CHUK, IKBKG
CDKN1A, NFKBIA, RELA, NFKB1, ARNT, JAK2, GRIN1,
EPOR

HEMOVASCULAR FUNCTION
Vegf Pathway

0.000

NOS3, ELAVL1, EIF1A, FLT1, PXN, EIF2B4, PTK2, SHC1,
ARNT, EIF2B2, PRKCA, EIF2S2, PIK3CA

No1 Pathway

0.000

CHRNA1, CAV1, PRKG2, NOS3, TNNI1, ACTA1, FLT1

0.000

MAP2K3, JUN, TNFRSF1A, NFKBIA, RELA, RIPK1,
NFKB1, TNF, CRADD, CHUK, IKBKG, MAP3K14

0.000

NOTCH1, ADAM17, BRTC, TCF1, CTNNB1, APC, DVL1,
PSEN1, FDZ1

CELL DEATH
Tnf Stress Pathway
SIGNAL TRANSDUCTION
Ps1 Pathway

Surprisingly, the MAPK pathway was positively enriched in both the wild-type and
GluK4 knockout conditions, though more so in the wild-type than in the knockout
condition (wild-type, p = 0.000; GluK4 knockout, p = 0.036; see Appendix 1). This
finding suggests several interpretations. One possibility is that the up-regulation
of the MAPK pathway in GluK4 knockout tissue is more limited than in wild-type
tissue, and that it may be statistically, but not biologically significant. Another
possibility is that that MAPK pathway activation serves different functions in wildtype versus GluK4 knockout conditions – that it may promote neurodegeneration
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in the wild-type condition and neuroprotection in the GluK4 knockout condition.
As discussed above, the MAPK pathway is comprised of several auxiliary
pathways, each with multiple, wide-ranging functions including cell proliferation in
addition to apoptosis. While GSEA does identify the specific genes within each
pathway that are enriched for a given condition (wild-type versus GluK4
knockout), the overlap in genes between the various auxiliary pathways makes it
difficult to assess which pathways are enriched. Thus, it is difficult to determine
from these data whether the JNK pathway is involved in either condition.

Biochemical Analysis of JNK Pathway Activation Suggests Biphasic Role of
GluK4
To better understand the interaction between GluK4 and the JNK pathway, I
investigated the phosphorylation states of JNK pathway components by Western
blot in kainate-injected wild-type and GluK4 knockout CA3 tissue. I hypothesized
that analysis of the JNK pathway at the protein level would yield a more accurate
– and more physiologically relevant – representation of JNK pathway activation
than analysis at the mRNA level, as JNK pathway activation is dependent upon
kinase-mediated phosphorylation of proteins.

The JNK pathway is activated by the phosphorylation of a MAPK kinase kinase,
such as MLK3, which in turn phosphorylates MAPK kinase 4 or 7 (Hirai et al.,
1997; Nagata et al., 1998). I found that phosphorylated MAPK kinase 4 (MKK4)
was significantly up-regulated in wild-type CA3 samples following kainate
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treatment as compared to PBS treatment, but remained unchanged in CA3
samples from GluK4 knockout mice (Student’s T-test, p = 0.003; Figure 7.5a)

MAPK kinases perpetuate the kinase cascade by phosphorylating one of three
JNK isoforms: JNK 1, 2, or 3. While JNK 1 and JNK 2 are expressed
systemically, JNK 3 is primarily expressed in neurons (Gupta et al., 1996; Martin
et al., 1996). Though native JNK1 and JNK 2/3 expression remained unchanged
after kainate administration (Figure 7.5b), I observed an increase, though not
statistically significant, in wild-type levels of phosphorylated JNK 2/3 after kainate
treatment (Student’s T-test, p = 0.087; Figure 7.5c). However, the increase in
phosphorylated JNK 2/3 levels in kainate-treated wild-type samples relative to
kainate-treated GluK4 knockout samples was statistically significant (Student’s Ttest, p=0.007; Figure 7.5c). Phosphorylated JNK 1 expression remained
unchanged in all conditions (Figure 7.5c).

Phosphorylated JNK isoforms regulate the activity of activator protein 1 (AP-1), a
transcription factor that modulates various cellular processes including apoptosis
(Whitmarsh and Davis, 1996). AP-1 assembles as a homo- or heterodimer from a
number of DNA-binding bZip proteins, including c-Jun, activating transcription
factor 2 (ATF2), and c-Fos. Native cJun, phosphorylated cJun, and
phosphorylated ATF-2 were all up-regulated in kainate-treated wild-type samples
relative to PBS-treated samples (Student’s T-test, p = 0.002, p = 0.011, and p =
0.004, respectively), but remained unchanged between kainate- and PBS-treated
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GluK4 knockout samples (Figure 7.5d - f). Though c-Fos expression was not
significantly different between kainate- and PBS-treated wild-type samples, it was
down-regulated in kainate-treated GluK4 knockout samples relative to PBStreated GluK4 knockout samples and kainate-treated wild-type samples
(Student’s T-test, p = 0.001 and p = 0.053, respectively; Figure 7.5g).
Surprisingly, phosphorylated ATF-2, c-Jun, phosphorylated c-Jun, and c-Fos
levels were all constitutively higher in PBS-treated GluK4 knockout samples than
in PBS-treated wild-type samples (Student’s T-test, p = 0.044, p = 0.048, p =
0.038, and p = 0.053, respectively; Figure 7.5d - g).
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Figure 7.5. GluK4 ablation results in decreased JNK pathway activation
following kainate, but increased JNK pathway activation at baseline. (A)
The active form of one of the earliest kinases in the JNK pathway, MKK4, was
up-regulated in wild-type CA3 tissue after KA treatment relative to PBS
treatment, but not in GluK4 CA3 tissue. (B) The native neuronal isoform of JNK
(JNK 2/3, 54 kDa, top band) remained unchanged between genotypes after PBS
or KA treatment. The bottom band represents the JNK 1 isoform (46 kDa), which
is expressed globally. (C) Despite the fact that the native form of JNK 2/3
remained unchanged in all conditions, the phosphorylated (activated) form of
JNK 2/3 is up-regulated in KA-treated wild-type tissue relative to KA-treated
GluK4 knockout tissue. (D) The native form of cJun, a member of the AP-1
transcription factor complex that is activated downstream of JNK, was upregulated in wild-type tissue following KA treatment relative to PBS treatment.
The increase in cJun expression between PBS- and KA treated GluK4 knockout
tissue was not significant, due to variability between samples. Basal c-Jun
expression was higher in PBS-treated GluK4 knockout tissue than in PBS-treated
wild-type tissue.
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Figure 7.5, continued. (E) The phosphorylated (activated) form of cJun was upregulated in KA- versus PBS- treated wild-type tissue but not GluK4 knockout
tissue. However, phosphorylated c-Jun expression was higher after PBS
treatment in GluK4 knockout tissue than in wild-type tissue. (F) Phorphorylated
ATF-2, another member of the AP-1 complex, followed a similar expression
pattern to phosphorylated cJun. Phosphorylated ATF-2 was up-regulated in upregulated in KA- versus PBS- treated wild-type tissue but not GluK4 knockout
tissue, though its expression was higher after PBS treatment in GluK4 knockout
tissue than in wild-type tissue. (G) cFos is also a member of the AP-1
transcription complex. Its expression was strongly down-regulated between KAtreated wild-type and GluK4 knockout tissue, and between PBS- and KA-treated
GluK4 knockout tissue. As with the other members of the AP-1 complex, c-Fos
expression was increased at baseline in PBS-treated GluK4 knockout versus
wild-type tissue. Bars represent mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
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Collectively, these data suggest that GluK4 can regulate JNK pathway activity in
a biphasic, context-dependent manner. In the context of excitotoxicity, GluK4
appears to be essential to the activation of the JNK pathway throughout its
various kinase tiers, which further suggests that GluK4 acts on one or more of
the early components of the pathway to initiate neurodegeneration. In nonpathological contexts, GluK4 seems to play a role in suppressing JNK pathway
activation.
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CHAPTER 8: GLUK4 IN KAINATE-INDUCED SEIZURES
Mesial temporal lobe epilepsy (mTLE) is one of the most common forms of
epilepsy, and is characterized by recurrent focal seizures that originate in
populations of hyperexcitable, hypersynchronous cells in the hippocampus
(Falconer et al., 1964). In most affected patients, mTLE arises in tandem with
lesions or alterations in neuronal connectivity that are the result of previous
neuronal insults, including trauma, encephalitis, and ischemia (Engel, 1993;
Camilo and Goldstein, 2004). Approximately 70% of patients with mTLE also
develop hippocampal sclerosis, which is characterized by neurodegeneration,
astrogliosis, and a form of synaptic reorganization in the dentate gyrus known as
mossy fiber sprouting (Babb and Brown, 1986).

Kainate, in addition to being a potent excitotoxin, is also an epileptogenic
compound that reproduces many of the hallmarks of mTLE in animals: recurring
motor seizures, hippocampal neurodegeneration, and mossy fiber sprouting
(Vincent and Mulle, 2009). In this model, animals are typically injected IP with
kainate and monitored for seizure activity for 2 – 4 hours thereafter. Seizure
severity is normally scored by hand and ranked using a metric developed by
Racine (Racine, 1972).

I hypothesized that GluK4 might play a role in the kainate model of mTLE based
on several lines of evidence. Mice deficient in GluK2, the kainate receptor
subunit with which GluK4 co-precipitates in the CA3, are resistant to kainate-

119

induced seizures (Mulle et al., 1998). Meanwhile, rats that were injected IH with a
viral vector that transduced GluK2 experienced seizures 4 hours after injection
(Telfeian et al., 2000). Furthermore, GluK4 expression is highest in the CA3, and
this region has been shown to be an epicenter of seizurogenic activity (Avoli and
Barbarosie, 1999). Synchronized discharges that originate within the network of
glutamatergic collaterals of the CA3, and subsequently spread throughout the
hippocampal subfields, are thought to underlie interictal spiking, a pathological
EEG pattern that may predict or precipitate epileptic seizures (Avoli et al., 2006).
While the anesthetics administered during the IH kainate injections prevented
motor seizures in the experiments described above (see Chapter 6), the
neuroprotection afforded by GluK4 ablation in this paradigm suggested that
GluK4 knockout mice might also have altered susceptibility to kainate-induced
seizures.

Additionally, GluK4-mediated seizures could explain the robust difference in
neurodegeneration following HI between wild-type and knockout animals. HI has
been shown to result in spontaneous motor seizures within 72 hours of surgery in
unanesthetized adult animals, and the occurrence of HI-induced seizures
correlated with the severity of HI-induced neurodegeneration (El-Hayek et al.,
2011). Though seizures were not specifically evaluated in Anna’s HI experiments
described above (see Chapter 6) they were often observed in passing. Thus, HI
could induce seizures that originate in GluK4-expressing cell populations of the
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CA3, then propagate throughout brain and produce widespread neuronal cell
death in wild-type, but not GluK4 knockout animals.

High, Incremental Doses of Kainate Suggest Decreased Seizure Susceptibility In
GluK4 Knockout Mice
To explore the role of GluK4 in seizure generation, wild-type and GluK4 knockout
animals were injected IP with an initial dose of 30 mg/kg kainate, followed by two
15 mg/kg doses at 45 minute intervals. Seizures were scored using a modified
version of Racine’s scale (see Chapter 2, p. 39). This dosing scheme resulted in
high mortality: 3 of 9 animals (33.33%) died. Nevertheless, seizure scores from
the remaining animals (wild-type, n = 3; GluK4 knockout, n = 3) suggested that
GluK4 knockout mice might be more resistant to kainate-induced seizures than
wild-type mice. Though the high variability and low n in the seizure score data
precluded any significant results by two-way ANOVA (effect of genotype, F =
2.67, p = 0.1776; Figure 8.1a), GluK4 knockout mice were almost entirely
unaffected by the initial 30 mg/kg dose of kainate (time (t) = 0 minutes), while
wild-type mice showed low-grade seizures. Following the next injection (15
mg/kg; t = 45 minutes), both wild-type and GluK4 knockout animal scores
escalated, and animals of both genotypes showed intermittent high-grade
seizures (level 4 - 5). Following the last injection (15 mg/kg; t = 90 minutes), wildtype animals showed sustained high-grade seizures, plateauing at level 5, while
GluK4 knockout animals showed sustained mid-grade seizures, plateauing at
level 3.
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Increased Seizure Activity in GluK4 Knockout Mice at Low Doses of Kainate
Because the above dosing scheme resulted in high mortality, and because the
difference in seizure scores between wild-type and GluK4 knockout mice
appeared to be most pronounced after the first injection, I lowered the dose of
kainate administered using several dosing schemes. An initial dose of 15 mg/kg
kainate followed by two doses of 5 mg/kg at 10 minute intervals yielded no
significant difference in seizure sensitivity by two-way ANOVA (wild-type n = 2,
GluK4 knockout n = 3; effect of genotype, F = 0.02, p = 0.9018; Figure 8.1b) or
appreciable trend to suggest that a difference might exist: both wild-type and
Glu4 knockout mice plateaued at level 4 seizures. Similar results were observed
with an initial dose of 15 mg/kg, followed by a single dose of 5 mg/kg after 20
minutes (wild-type n = 3, GluK4 knockout, n = 3; two-way ANOVA, effect of
genotype, F = 1.25, p = 0.3262; Figure 8.1c), though seizure scores in GluK4
knockout animals did not seem to increase as steadily as in wild-type animals.
Finally, a single injection of 15 mg/kg without subsequent injections did not yield
significant results by two-way ANOVA (wild-type n = 4; GluK4 knockout n = 2;
effect of genotype, F = 3.69, p = 0.1270; Figure 8.1d). At this dose, GluK4
knockout mice appeared more sensitive to the effects of kainate, though the low
n and high variability again made results difficult to interpret.
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FIGURE 8.1. GluK4 knockout mice trend towards altered seizure
susceptibility. (A) GluK4 knockout mice showed a decrease, though not
significant, in susceptibility to high incremental doses of IP kainate relative to
wild-type mice (p = 0.1776). (B) A low-dose incremental injection scheme did not
reveal differences in seizure activity between wild-type and GluK4 knockout mice
(p = 0.9081). (C) A second low-dose incremental injection scheme failed to
reveal a difference between genotypes (p = 0.3262). (D) Surprisingly, single
injections of a low dose of kainate reveal a trend towards increased seizure
susceptibility in GluK4 knockout animals. Arrows indicate injection time points. ***
= 30 mg/kg kainate; ** = 15 mg/kg kainate; * = 5 mg/kg kainate.
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Though none of the results obtained were significant, there appeared to be two
trends in the data: at very high doses of kainate (initial injection of 30 mg/kg,
followed by 2 injections of 15 mg/kg), GluK4 knockout mice appear to be less
sensitive to kainate-induced seizures that wild-type mice; at very low doses of
kainate (single injection of 15 mg/kg), GluK4 knockout mice may be more
sensitive to kainate-induced seizures than wild-type mice. Further experiments
would be needed to confirm these findings, but they suggest nevertheless that
the role of GluK4 in kainate-induced seizures may be dose-dependent.
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CHAPTER 9: DISCUSSION
Like the other ionotropic glutamate receptors, NMDA and AMPA receptors, postsynaptic kainate receptors initiate EPSCs upon ligand binding. However, kainate
receptors are unique in that they also modulate neurotransmitter release in a bidirectional manner when expressed pre-synaptically. Furthermore, kainate
receptors have been found to alter inhibitory transmission at GABAergic
terminals, as well as to serve non-canonical, metabotropic functions (RodríguezMoreno and Sihra, 2011). Ultimately, through their complex and diverse
functions, kainate receptors are responsible for fine-tuning the excitability of
neuronal networks within the CNS, and for preventing aberrant excitatory
transmission. Here, I have presented evidence that loss of a single kainate
receptor subunit, GluK4, disrupts this tenuous balance, and uncovers a crucial
role for GluK4 in diverse neurological processes.

Persistent GRIK4 mRNA Expression in GluK4 Knockout Animals
To study the function of GluK4 in the CNS, I generated a global GluK4 knockout
mouse line by crossing mice in which exon 16 of GRIK4 was floxed, with
transgenic mice in which cre was expressed in the germline. I found through an
exhaustive investigation of GluK4 expression in the GluK4 knockout line that
GluK4 was effectively ablated at the protein level, rendering these mice
functional knockouts. However, GRIK4 mRNA was missing the region
corresponding to exon 16 but was otherwise intact in GluK4 knockout animals,
and expressed at normal levels.
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There are several potential explanations for the observation that GRIK4 mRNA
persists in GluK4 knockout animals, but GluK4 protein does not. One possibility
is that the absence of exon 16 renders GRIK4 mRNA unstable in a way that
discourages translation, or decreases translational efficiency to a point where
GluK4 protein is undetectable by western blot. Another possibility is that GluK4
protein is indeed generated from the altered GRIK4 mRNA present in GluK4
knockout mice, but that the protein is inherently unstable without the p-loop
region corresponding to exon 16 and therefore gets ubiquitinated or otherwise
flagged for degradation. Because no GluK4 protein was detected by western blot,
GluK4 degradation in this scenario would need to occur fairly quickly after
translation, or else turnover of GluK4 is so slow that it doesn’t accumulate quickly
– it can persist at levels below the threshold for western blot detection before it
gets degraded. One means of testing this hypothesis would be to generate a
mouse where floxed GRIK4 is fused to a reporter gene, with the caveat that the
reporter could further destabilize or interfere with the structure of the cre-excised
(referred to hereafter as “mutant”) form of GluK4 protein. The presence of the
reporter could then be assessed in a quantitative, GluK4-independent assay that
is more sensitive than western blotting.

Alternatively, mutant GluK4 may be stable, but it may somehow fail a cellular
checkpoint in the process of kainate receptor assembly, and therefore get
targeted for destruction. There have been several previous reports of critical
checkpoints during kainate receptor assembly. Within the endoplasmic reticulum
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(ER), high affinity GluK5 subunits are probed for their ability to properly bind
glutamate before they, and any receptor complex in which they participate, can
be trafficked to the plasma membrane (Valluru et al., 2005). Coatomer protein
complex I (COPI) and 14.3.3ζ proteins also interact with GluK5 to regulate GluK5
trafficking. COPI interacts with the ER retention motif in GluK5 to promote
sequestration of GluK5 within the ER, and this association is reduced upon the
assembly of GluK5 with GluK2 (Vivithanaporn et al., 2006). As the association
between GluK5 and COPI is reduced, the association between GluK5 and
14.3.3ζ is increased, and 14.3.3ζ promotes the forward trafficking of heteromeric
kainate receptors containing GluK5 to the plasma membrane (Vivithanaporn et
al., 2006). These findings in GluK5 suggest that similar mechanisms may exist to
regulate the inclusion of GluK4 in functional kainate receptor subunits, and that
misfolding of GluK4 or the absence of the p-loop may compromise the ability of
mutant GluK4 to pass critical checkpoints.

Finally, it is possible that mutant GluK4 protein is stable and does not get
degraded at all, but is truncated or folded in such a way that it cannot be
detected by either of the antibodies used in my western blotting assays. One
means of addressing this issue would be to generate a range of custom
antibodies directed against all regions of GluK4 and to run western blots using
denaturing conditions to ensure that the altered secondary structure of mutant
GluK4 did not obscure the antibody binding regions.
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Memory Deficits in GluK4 Knockout Animals
Because GluK4 ablation results in aberrant mossy fiber LTP (Catches et al.,
2012), I hypothesized that GluK4 may play a role in learning and memory, both of
which are LTP-dependent processes. I compared the performance of wild-type
and GluK4 knockout mice in various hippocampus-dependent learning tasks to
assess the nature and extent of the memory deficits induced by GluK4 ablation,
and found that working memory was intact in GluK4 knockout mice, but that fear
memory and spatial memory were impaired. These findings are consistent with
previous studies which have highlighted the importance of the CA3 – the
hippocampal region where GluK4 expression is most concentrated – to
associative learning processes such as fear conditioning (Daumas et al., 2004)
and the MWM (Steffenach et al., 2002; Stupien et al., 2003; Florian and Roullet,
2004).

One caveat to my findings could be that, while GluK4 knockout mice showed
decreased freezing behavior relative to wild-type mice during successive toneshock pairings on the first day of fear conditioning, and I have interpreted this
deficit to be an indication of impaired fear memory acquisition, it is possible to
attribute this deficit to other sources. The decreased freezing behavior observed
in GluK4 knockout mice in response to the foot shock may be akin to their
decreased response to the acoustic startle – that is, a reflection of decreased
arousal or attention rather than learning. Thus, wild-type and GluK4 knockout
mice may have sensed the footshock with equal intensity, as the incremental
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hotplate test indicated that both genotypes have equivalent pain thresholds, but
GluK4 knockout mice may have attached less emotional valence to the
experience.

Another possibility is that the decrease in freezing behavior is a reflection of the
basal hyperactivity observed in GluK4 animals during the open field tasks. This
seems unlikely, however, as basal freezing behavior within the fear conditioning
chamber was not significantly different between wild-type and GluK4 mice during
the acclimatization period preceding the tone-shock pairings on day 1.
Furthermore, freezing behavior did not differ between wild-type and GluK4
knockout animals in the contextual or cued paradigms on day 2, although the
argument could be made that hyperactivity in the GluK4 knockout animals may
have masked a true deficit in freezing behavior and, thus, in learning and
memory. Nevertheless, one means of addressing this issue would be to measure
behavioral outputs of fear that were not dependent on movement, such as
ultrasonic vocalizations or hypertension.

Basal hyperactivity in the GluK4 knockout line may have also been a
confounding factor in the MWM results, and could explain why knockout mice
took longer trajectories to reach the hidden platform during the hidden platform
trials. However, the increase in distance traveled during these trials was not
accompanied by an increase in swimming velocity relative to wild-type animals,
while the increase in distance traveled during the open field test was, suggesting
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that increased velocity is a feature of hyperactivity in GluK4 knockout animals.
Furthermore, visual platform performance did not differ between GluK4 knockout
and wild-type animals. The increase in the distance traveled by the GluK4
knockout cohort during the hidden platform trials is therefore more likely to be a
product of impaired cognitive processes rather than hyperactivity.

The learning and memory deficits in GluK4 knockout mice may provide further
evidence for a role of GluK4 in human neuropsychiatric disorders: cognitive
function, and particularly declarative and working memory, are consistently
impaired in individuals with schizophrenia (Stone et al., 1998). Additionally, the
number of synapses between mossy fibers and CA3 pyramidal neuronal spines
is reduced in schizophrenic patients (Kolomeets et al., 2007), which may result in
reduced excitatory transmission in this region and thereby parallel the effects of
GluK4 ablation.

Ultimately, further research into the role of GluK4 in memory is warranted in
humans. A previous study on the relationship between GluK4 and hippocampal
activation has shown that patients who carry a deletion variant of GRIK4 that
increases GRIK4 mRNA expression demonstrate greater hippocampal activation
during a facial processing task than patients who carry the normal GRIK4 allele
(Whalley et al., 2009b; 2009a). To elucidate the effects of GluK4 on memory in
humans, this experimental paradigm could be modified so that the test subjects
were performing a hippocampus-dependent memory task.
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Another future line of research could be to investigate the effects of GluK4
ablation in CA3 networks outside of the mossy fiber pathway. The majority of
excitatory synapses within the CA3 originate from pyramidal cells that form
recurrent collaterals onto neighboring pyramidal cells to form a self-contained
network of excitatory input within the CA3 (Ishizuka et al., 1990). It has been
proposed that modification of synaptic strength within this autoassociative
network contributes to hippocampus-dependent memory (Gardner-Medwin,
1976). Recurrent collaterals within the CA3 project to the stratum oriens and
stratum radiatum of the CA3 (Ishizuka et al., 1990), and GluK4 is expressed
(albeit weakly) in the stratum radiatum (Darstein et al., 2003), suggesting that
GluK4 may contribute to memory forming process through its actions at mossy
fiber synapses as well as at recurrent CA3 synapses. GluK4-mediated activity at
both types of synapses may in fact be interdependent, as the mnemonic
functions of the autoassociative CA3 network rely in part on mossy fiber input
(McNaughton and Morris, 2002). Assessing the electrophysiological properties of
this autoassociative network in GluK4 knockout mice might further elucidate the
role of GluK4 in memory.

Altered Behavior and Mood in GluK4 Knockout Animals, and Implications for
Human Neuropsychiatric Disorders
The behavioral phenotype of GluK4 knockout mice strongly suggests that GluK4
regulates mood. I observed decreased anxiety- and depressive-type behavior in
GluK4 knockout mice in the open field and forced swim tests, respectively.
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Furthermore, the fact that GluK4 mice exhibit a decreased acoustic startle
response compared to wild-type mice is an indication that basal levels of arousal
and emotionality differ between the genotypes. The acoustic startle response is
regulated by corticotropin releasing factor, which activates the hypothalamicpituitary-adrenal axis in response to stress, and contributes to anxiety and
depression disorders (Risbrough et al., 2003). These findings are consistent with
a previous study in which GRIK4 mRNA expression was significantly upregulated following chronic restraint stress, and was shown to be regulated by
the adrenal steroid corticosterone (Hunter et al., 2009). Furthermore, an allelic
variant of GRIK4 is associated with the outcome of selective serotonin reuptake
inhibitor treatment in patients with major depressive disorder (Paddock et al.,
2007). Thus, the anxiolytic, antidepressant effects of GluK4 ablation suggest that
GluK4 may be involved in regulating baseline affect and mood, and that aberrant
GluK4 expression may contribute to anxiety and depression in humans.

As with the memory assays described above, hyperlocomotion in GluK4
knockout animals may be a confounding factor in the interpretation of the open
field and forced swim results because the scored behaviors in these experiments
are dependent upon mobility. However, there are several lines of evidence to
suggest that the differences in anxiety and depressive-type behaviors between
wild-type and GluK4 knockout mice are valid. In both open field paradigms (short
/ lit, and long / dark), GluK4 mice showed an overall preference for the periphery
of the open field over the center, much as wild-type mice did. This observation

133

indicates that, despite being hyperlocomotive, GluK4 mice nevertheless exhibited
directed motor behaviors – they were not randomly moving through the open
field. The difference between wild-type and GluK4 knockout mice in their
preference for the center of the field can therefore be attributed to the fact that
the GluK4 knockout mice perceived the center zone to be less aversive than the
wild-type mice do.

Furthermore, a concurrent study of GluK4 knockout mouse behavior that
supports many of our findings has recently been published (Catches et al., 2012).
The authors employed several non-locomotor tests that bypass the issue of
hyperlocomotion in GluK4 knockout mice. They demonstrated, using a noveltyinduced suppression of feeding test, that GluK4 knockout mice are less anxious
than wild-type mice: GluK4 knockout mice exhibit a shorter latency to consume
food placed in a novel, anxiogenic environment than wild-type mice do. The
authors also demonstrated, using a sucrose preference test, that GluK4 knockout
mice are less prone to depressive type behaviors: GluK4 knockout mice exhibit a
greater preference for a 1% sucrose solution than wild-type mice do, presumably
because they derive greater pleasure from this stimulus than wild-type mice do,
and, by extension, are less depressive.

Finally, hyperlocomotion is often considered in animal models of psychological
disorders to be a reflection or behavioral correlate of psychomotor agitation, an
endophenotype of both bipolar disorder and schizophrenia (van den Buuse,
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2010). According to the dopamine hypothesis of schizophrenia, psychomotor
agitation and other positive symptoms of schizophrenia can be attributed to
excess dopaminergic activity, and, indeed, drugs that enhance dopamine
neurotransmission such as amphetamine induce hyperactivity in rodents (van
den Buuse, 2010). Meanwhile, the glutamate hypothesis of schizophrenia
postulates that the positive symptoms of schizophrenia are related to insufficient
glutamatergic activity, and NMDA receptor antagonists such as MK-801 and
phencyclidine also induce hyperactivity in rodents, as does GluK2 ablation
(Shaltiel et al., 2008; Gunduz-Bruce, 2009). Thus, hyperlocomotion in GluK4
knockout mice may be a relevant phenotype to the understanding of the role of
GluK4 in neuroaffective disorders.

The involvement of GluK4 in schizophrenia and bipolar disorder is further
supported by data from the PPI assays. Compared to wild-type mice, GluK4
knockout mice showed decreased inhibition of the acoustic startle response
when the startle-inducing tone was preceded by a weaker tone. Deficits in PPI
are common in patients with schizophrenia, and have also been observed in
patients with bipolar disorder during periods of acute psychotic mania (Perry et
al., 2001). The relationship between PPI and psychosis is not fully understood.
However, PPI deficits may be a reflection of the fact that psychotic patients are
unable to discriminate between trivial and salient stimuli within their environment,
and are therefore subjected to constant cognitive overload as they respond to
each with equal measure (Perry and Braff, 1994; Geyer et al., 2002). While
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psychosis and cognitive overload are difficult to model definitively in animals,
GluK4 ablation at the very least phenocopies a human correlate of these
dysfunctions by inducing PPI impairments in GluK4 knockout mice.

The results obtained in the open field and forced swim trials may be relevant to
psychological disorders, as the basal decreases in anxiety and despair in GluK4
knockout animals may parallel the dramatic mood elevation and increased risktaking behavior that are characteristic of bipolar disorder (Belmaker, 2004).
Taken together with the cognitive and sensorimotor gating impairments observed
in GluK4 knockout animals, and the ample evidence from human studies
implicating GluK4 in bipolar disorder and schizophrenia, my findings suggest that
aberrant GluK4 expression may explain certain facets of these diseases.

My findings in GluK4 knockout animals are also largely congruent with those
observed by other groups in GluK2 knockout animals (Ko et al., 2005; Shaltiel et
al., 2008). Like GluK4 knockout mice, GluK2 knockout mice are less anxious,
more risk-taking, and show fewer manifestations of despair than wild-type mice.
However, GluK2 knockout mice display hyperaggression in resident-intruder
assays, while I was unable to observe any behavioral markers of aggression in
GluK4 knockout mice in a pilot study of the same test (data not shown). GluK2
knockout mice also show significant reduction in fear memory recall, as indicated
by decreased freezing times relative to wild-type mice in both contextual and
cued fear conditioning paradigms (Ko et al., 2005), while I found only impaired
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acquisition of fear memory in GluK4 knockout mice. The discrepancies observed
between GluK2 and GluK4 knockout behavior suggest the possibility that GluK2
and GluK4 may co-assemble to regulate anxiety, risk-taking, and despair, but
that GluK2 and GluK4 may assemble with other kainate receptor subunits to
regulate aggression and fear memory retrieval in the case of GluK2, and fear
memory acquisition in the case of GluK4.

GluK4-mediated Excitotoxic Neurodegeneration, and Regulation of the JNK
Pathway
Excitoxicity is responsible for the widespread cell death that underlies many of
the debilitating aspects of neurodegenerative diseases such as ischemic stroke.
It is triggered by the excessive stimulation of glutamate receptors, whereupon
large influxes of calcium into neurons instigate a host of cytotoxic events,
including mitochondrial dysfunction, nitric oxide and free radical production, and
activation of cell death pathways (reviewed in (Lau and Tymianski, 2010)).
Depending on the nature and the magnitude of the insult, affected neurons
ultimately undergo apoptotic, necrotic, or programmed cell death (Wang et al.,
2005; 2005; Tokuhara et al., 2007).

I observed that the CA3 region of the hippocampus in GluK4 knockout animals is
protected against neurodegeneration following kainate-induced excitotoxicity. To
elucidate the pathways downstream of GluK4 activation that lead to
neurodegeneration, I compared the transcriptomes of wild-type and GluK4
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knockout CA3 tissue after kainate or vehicle injection. I found that the MAP
kinase pathway, as well as other apoptotic cell death pathways, were upregulated in wild-type, but not GluK4 knockout tissues following kainate injection,
suggesting that these pathways may interact with GluK4 to mediate cell death.
Biochemical analysis of the JNK pathway, a subset of the MAP kinase pathway
that is known to mediate excitotoxic cell death (Bogoyevitch et al., 2004),
revealed that the JNK pathway was activated in wild-type tissue, but not GluK4
tissue, following kainate administration. Furthermore, basal JNK pathway
activation was higher in GluK4 knockout tissue than in wild-type tissue. Together,
these results suggest a biphasic role for GluK4 in the modulation of the JNK
pathway: under basal conditions, GluK4 serves to suppress JNK pathway
activations, while under excitotoxic conditions, GluK4 serves to activate the JNK
pathway.

Several scenarios present themselves as to how GluK4 and the JNK pathway
interact. One possibility is that GluK4 interacts with the JNK pathway directly by
participating in heteromeric receptor complexes with GluK2, and, by extension,
the GluK2 / PSD-95 / MLK3 signaling complex that activates the JNK pathway
(Tian et al., 2005). GluK4 may also participate in other non-canonical,
metabotropic actions that indirectly induce the JNK pathway. The JNK pathway
has many upstream effectors, including G-proteins (Yang et al., 2006), and
kainate receptors are known to couple with G-proteins to mediate various cellular
signaling events, such as pre-synaptic glutamate and GABA release (Rodríguez-
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Moreno and Sihra, 2011; Sihra and Rodríguez-Moreno, 2011). It is also possible
that GluK4 subserves a purely ionotropic function in the initiation of excitotoxic
cell death by either fluxing calcium directly into post-synaptic cells, or by
triggering excess glutamate release from presynaptic cells and thereby activating
any or all forms of post-synaptic ionotropic glutamate receptors, which then flux
calcium into post-synaptic cells. Calcium ions can initiate a large number of
signal transduction pathways, and elevated intracellular calcium levels have been
shown to induce JNK pathway activation in macrophages (Kim and Sharma,
2004).

The means by which JNK pathway activation results in cell death remains
controversial (Lin, 2003). JNK may indirectly activate caspase-dependent cell
death pathways, either through the intermediary of mitochondrial cytochrome cdependent pathways (Tournier et al., 2000) or TNFa-dependent pathways
(Chang et al., 2006). Nevertheless, GSEA analysis of my microarray results
indicated that several cell death pathways were up-regulated in wild-type but not
GluK4 knockout tissue following kainate administration. One can speculate that
these pathways are downstream of JNK activation, although proving this
hypothesis would be challenging. Repeating the microarray experiment with an
extra condition, where mice were treated with a JNK pathway inhibitor such as DJNKI1 or sp600125 in addition to kainate or vehicle to determine whether the
same cell death pathways were differentially regulated between wild-type and
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GluK4 knockout mice in the absence of JNK activity, would be a first step in
establishing a link between JNK and downstream cell death pathways.

In contrast to the regionalized neuroprotection that I observed in GluK4 knockout
mice following kainate-induced excitotoxicity, the neuroprotection observed
following HI extended throughout the hippocampus. One explanation for this
phenomenon could be that, in the context of HI, GluK4 activates cell death
pathways other than, or in addition to, the JNK pathway. These pathways may be
more pervasive than the JNK pathway, or they may incite alternative forms of cell
death. Another possibility is that the neurodegeneration resulting from HI may
stem from GluK4-mediated seizures. While avertin, the long-acting anesthetic
used during the IH kainate injection procedure, may have precluded seizure
activity in the IH kainate paradigm, the short-acting isofluorane anesthetic used in
the HI procedure would have permitted it. Indeed, Anna observed sporadic
seizures in HI-treated animals, though she was blind to the genotype of the
affected animals at the time. The potential role of GluK4 in seizures is further
discussed below.

Finally, the microarray experiment generated a vast collection of data, and
following up on each potentially relevant lead was outside the scope of my thesis.
However, there are several microarray results that may warrant further
investigation. For instance, biochemical analysis of the cell death pathways that
emerged from GSEA analysis as being differentially regulated in wild-type and
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GluK4 knockout tissue following kainate administration may provide insight into
the relationship between GluK4, JNK pathway activation, and cell death
pathways. Furthermore, there were a handful of genes that were differentially
regulated between wild-type and GluK4 knockout tissue at baseline (i.e., after
vehicle injection). One such gene, transmembrane protein 25 (Tmem25), was
down-regulated 45.03-fold in GluK4 knockout samples relative to wild-type
samples. Very little is known about the function of Tmem25, other than the fact
that it is a member of the immunoglobulin superfamily (Katoh and Katoh, 2004),
and that it may be a biomarker for breast cancer (Doolan et al., 2009). However,
a preliminary search of the online Allan Mouse Brain Atlas (Allan Institute for
Brain Science) indicates that Tmem25 expression is highly concentrated within
the CA3 region of the hippocampus, which, again, is an area of highly
concentrated GluK4 expression. Furthermore, the fact that Tmem25 is a
transmembrane protein (Katoh and Katoh, 2004) whose expression is heavily
influenced by the presence or absence of GluK4 suggests that it may serve as an
auxiliary protein for GluK4, perhaps aiding in GluK4 trafficking.

The microarray experiment may ultimately be worth repeating, with the following
modifications: 1. using individual, rather than pooled, biological replicates to
facilitate downstream analysis; 2. excluding whole hippocampus samples; 3.
including samples injected with both kainate or vehicle plus a JNK inhibitor; 4.
including un-injected samples from each genotype to better understand basal
differences between wild-type and GluK4 knockout transcriptomes; and 5.
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including samples from mice that had been sacrificed at a series of time points
following kainate or vehicle injection to assess the time-course of GluK4mediated pathway activation.

Parsing the Role of GluK4 in Kainate-Induced Seizures
To investigate the role of GluK4 in mTLE and seizures, I injected wild-type and
GluK4 knockout mice IP with kainate using several dosing schemes. While none
of the dosing schemes yielded significant results, there appeared to be two
trends in the data: at very high doses of kainate GluK4 knockout mice appeared
to be less sensitive to kainate-induced seizures than wild-type mice, while at very
low doses of kainate GluK4 knockout mice appeared to be more sensitive. These
results again suggest a biphasic role for GluK4 in the regulation of synaptic
activity.

One reason for the dose-dependent effects of kainate on seizure activity in
GluK4 knockout mice could be that lower doses of kainate preferentially activate
GluK4-containing presynaptic autoreceptors, which are somewhat more
abundant than postsynaptic receptors (Darstein et al., 2003), and that these
receptors may serve to prevent neurotransmitter release and curb excitatory
transmission (Frerking et al., 2001). Meanwhile, higher doses of kainate may
activate facilitatory post-synaptic receptors to a greater extent than lower doses
do, and the excitatory post-synaptic receptor response may outweigh the
inhibitory presynaptic receptor response.
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Though results were not significant for any of the dosing schemes evaluated,
there are several variables which may have obfuscated a true difference in
kainate sensitivity between wild-type and GluK4 knockout animals. One of the
major drawbacks of this experiment is the scoring method: seizure scores must
be evaluated by hand, as there is no suitable video tracking software (to my
knowledge) to automate scoring, and the scores are therefore subjective. To
address this issue, all experiments were live-scored by two independent
observers, and the scores from both observers were then averaged.
Nevertheless, the Racine scale used for scoring leaves room for ambiguity,
particularly because seizure severity does not always increase in a linear manner
from levels 0 – 6. In some cases, it was difficult to score seizure events
definitively.

A second drawback of this paradigm is that it is relatively low-throughput. I found
that the maximum number of mice that could be tested at once was 6; beyond
that, it was difficult to keep track of the behavior of individual mice, and to inject
them swiftly. Coupled with the fact that there was high inter-animal variability in
kainate sensitivity within genotypes, perhaps due to differences in kainate
metabolism and bioavailability, the low n may have contributed to the lack of
significant results. While in some instances I did try repeating experiments and
combining the results, I found that there was high variability within genotypes
between experimental days. This may have been due to differences in the time of
day at which experiments were initiated, as circadian rhythms could, in theory,
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affect kainate metabolism. Another possibility is that the kainate solutions
injected on different experimental days were inconsistent: kainate was mixed
fresh daily from powder, and the powder often originated from separate lots
(though it was always produced by the same manufacturer, Tocris). Finally, the
within-genotype differences across experimental days may have been, once
again, an artifact of inter-animal differences in kainate metabolism and
bioavailability.

Were these experiments to be continued, they would require much larger
cohorts, and either a means of scoring all the animals simultaneously, e.g. by
video-recording the trials and scoring 6 animals at a time from the recordings, or
a means of spreading the experiment across several days such that the time of
day that the animals were tested was consistent, and the kainate used was
always from the same batch. It might also be beneficial to evaluate other, more
objective measures of seizure severity, such as electroencephalographic
recordings (Hatazaki et al., 2007). Finally, another potential avenue of
investigation could be to compare seizure severity in wild-type versus GluK4
knockout mice following HI.
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Coda
The GluK4 kainate receptor subunit has, arguably, been overlooked in previous
studies of kainate receptor function. Because of its restricted expression pattern
relative to other subunits, its contribution to overall network activity was assumed
to be less influential than that of the other subunits, and its signaling properties
were largely extrapolated from those of GluK5 (Huettner, 2003). However, from
the work described in this thesis, the wide-ranging impact of GluK4 – and of its
absence – on mood, memory, and excitotoxicity, has come into focus.
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APPENDIX 1. Biocarta pathways enriched in both wild-type and GluK4 knockout
samples following kainate administration
Biocarta Pathway

WT P
Value

WT Genes (with Core
Enrichment)

KO P
Value

KO Genes (with Core
Enrichment)

OXITATIVE STRESS

VITCB PATHWAY

0.000

SLC23A2, P4HB, COL4A4,
COL4A5, COL4A1,
COL4A2, SCL2A1,
COL4A6, COL4A3,
SLC23A1, SLC2A3

ARENRF2 PATHWAY

0.000

FOS, JUN, MAFF, NFE2L2,
MAFG

0.000

FOS, JUN, MAFF, MAFK,
CREB1, FXYD2, PRKCA

FREE PATHWAY

0.056

Not reported by GSEA

0.043

Not reported by GSEA

0.020

COL4A2, COL4A1, P4HB,
SLC2A1, SLC23A1,
SLC23A2

IMMUNITY
CCL4, FOS, CCL2, JUN,
CCR5
CD44, ICAM1, PECAM1,
ITGB1, SELP

0.000

MONOCYTE PATHWAY

0.000

IL22BP PATHWAY

0.000

SOCS3, STAT3, STAT1,
STAT5A

0.020

CLASSIC PATHWAY

0.000

C4B, C3, C1QA, C1QB, C2

0.019

Not reported by GSEA

0.038

JUN, MAP2K3, MYD88,
IL1RAP, RELA, IL1A, IL1B,
MAP3K14, NFKB1, IL1RN,
NFKBIA, IRAK3, TGFB3,
IRAK1, TRAF6, IL1R1,
MAP3K7IP1, TNF, TOLLIP,
MAP3K7, MAP3K1

0.000

MAP2K3, JUN, MYD99,
NFKBIA, IL1B, IL1RAP,
RELA, TGFB3, TOLLIP,
NFKB1, IRAK3, MAP3K7,
TRAF6, IL1A, TNF, CHUK

0.000

SOCS3, FOS, JAK3,
JAK1, NMI, PTPN6,
STAT5A, BCL2L1,
RPS6KB1, BCL2, SHC1,
IL2RG, MYC

0.000

STAT3, HMOX1, JAK1,
STAT1, STAT5A, BLVRA,
BVLRB, IL1A, TNF

0.037

Not reported by GSEA

IL1R PATHWAY

SOCS3, FOS

0.000

CCL4, FOS, CCL2, JUN,
CC45
CD44, ICAM1, PECAM1,
SELP, ITGB1
SOCS3, STAT3, JAK3,
JAK1, IL22RA1, STAT1,
STAT5A

CCR5 PATHWAY

0.000

IL2RB PATHWAY

0.000

IL10 PATHWAY

0.019

COMP PATHWAY

0.018

ETS PATHWAY

0.035

FOS, CSF1, JUN, ETS2

0.019

CDMAC PATHWAY

0.016

FOS, JUN, RELA, NFKB1,
NFKBIA

0.037

LAIR PATHWAY

0.000

BCR PATHWAY

0.036

TNFR2 PATHWAY

0.020

STAT3, HMOX1, BLVRB,
STAT1, STAT5A, IL1A,
BLVRA
C4B, C3, C1QA, C1QB,
MASP2

ICAM1, C3, VCAM1, IL1A,
ITGB1, SELP
FOS, JUN, BLNK, SHC1,
VAV1, NFATC4
Not reported by GSEA

146

0.000

FOS, JUN, CSF1, ETS1,
ETS2, E2F4
FOS, JUN, NFKBIA,
RELA, NFKB1, CUZD1,
TNF, MYC, PRKCA
C3, ICAM1, SELP, ITGB1,
IL1A, TNF

0.052

Not reported by GSEA

0.039

Not reported by GSEA

APPENDIX 1, Continued
Biocarta Pathway

WT P
Value

WT Genes (with Core
Enrichment)

KO P
Value

KO Genes (with Core
Enrichment)

CELL SIGNALING
0.055

PECAM1, CTNNA1,
ACTN1, CTNNB1, BCAR1,
ACTN3, PXN, CSK, VCL,
PTK2

0.000

PECAM1, PXN, ACTN1,
CTNNA1, PTK2, CTNNB1,
CTNNA2, CSK, BCAR1,
VCL

0.000

FOS, JUN, CREM

0.019

FOS, JUN, PRKAR2A,
CREM, CREB1

TPO PATHWAY

0.000

FOS, STAT3, JUN, SHC1,
STAT1, STAT5A

0.053

PDGF PATHWAY

0.000

FOS, STAT3, JUN, SHC1,
STAT1, STAT5A

0.019

EGF PATHWAY

0.020

FOS, STAT3, JUN, SHC1,
STAT1, STAT5A

0.020

MET PATHWAY

0.019

FOS, STAT3, JUN, DOCK1,
ACTA1, ITGB1, RAP1B

0.000

IL3 PATHWAY

0.000

FOS, SHC1, STAT5A,
PTPN6

0.034

Not reported by GSEA

CELL2CELL PATHWAY
PAIN
DREAM PATHWAY
CELL PROLIFERATION
AND DIFFERENTIATION
Promoting

FOS, STAT3, JUN,
STAT1, STAT5A, SHC1,
PRKCA, JAK2, PIK3CA
FOS, STAT3, JUN, JAK1,
STAT1, STAT5A, SHC1,
SRF, PRKCA, PIK3CA
FOS, STAT3, JUN, JAK1,
STAT1, STAT5A, SHC1,
SRF, PRKCA, PIK3CA
FOS, STAT3, JUN,
DOCK1, ACTA1, PXN,
GAB1, ITGB1

0.036

Not reported by GSEA

0.019

FOS, MAP2K3, JUN,
TNFRSF1A, ETS1,
PRKCD, NFKBIA, ETS2,
RELA, RIPK1, PRKCH,
NFKB1, MAP2K7, SP1,
TNF, BCL2, CHUK,
PRKCA

0.000

CDKN1A, GADD45A,
CDK2, TIMP3, CCND1,
PCNA, BAX

0.019

CKDN1A, GADD45A,
CDK2, MDM2, PCNA,
CCND1, TIMP3, BCL2

TPO PATHWAY

0.000

FOS, STAT3, JUN, SHC1,
STAT1, STAT5A

0.053

CARDIAC EGF
PATHWAY

0.000

EPO PATHWAY

0.032

KERATINOCYTE
PATHWAY

Inhibiting
P53 PATHWAY
HEMOVASCULAR
FUNCTION

FOS, JUN, RELA, EDN1,
NFKB1, EDNRB, ADAM12,
EGFR
FOS, JUN, SHC1, STAT5A,
PTPN6
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0.019
0.047

FOS, STA3, JUN, STAT1,
STAT5A, SHC1, PRKCA,
JAK2, PIK3CA
FOS, JUN, RELA, NFKB1,
ADAM12, EDN1, MYC,
PRKCA
Not reported by GSEA

APPENDIX 1, Continued
Biocarta Pathway

WT P
Value

WT Genes (with Core
Enrichment)

KO P
Value

KO Genes (with Core
Enrichment)

CELL DEATH

MAPK PATHWAY

0.000

FOS, JUN, MAP2K3,
MAPKAPK2, MAPKAPK3,
SHC1, PRS6KA1, STAT1,
MAP3K8, RELA, MAPK6,
MAPK9, MAX, MAP3K6,
MAP3K14, NFKB1, RIPK1,
NFKBIA, TRAF2, MAPK4,
MAPK12, MAPK7

FREE PATHWAY

0.056

Not reported by GSEA

TNFR1 PATHWAY

0.036

FOS, MAPK23, JUN,
MAPKAPK2, MAP3KA,
MAPK6, MAP3K6,
NFKBIA, RPS6KA1,
MAPKAPK3, MAPK11,
RELA, MAP4K5, MAP4K4,
TGFB3, RIPK1, NFKB1,
STAT1, MAP2K7, SP1,
MAPK12, RPS6KB1,
MEF2C, MAP3K7,
RPS6KA3, TGFBR1,
RPS6KB2, SHC1, CHUK,
CREB1, MYC

0.043

Not reported by GSEA

0.000

JUN, TNFRSF1A, LMNA,
ARHGDIB, LMNB1,
CASP8, RIPK1, FADD,
MAP3K7, TNF, CRADD,
BAG4, LMNB2

0.036

Not reported by GSEA

NFKB PATHWAY

0.000

MYD88, TNFRSF1A,
FADD, RELA, IL1A,
MAP3K14, NFKB1, RIPK1,
TLR4, IRAK1, TRAF6,
IL1R1, MAP3K7IP1, TNF,
MAP3K7, MAP3K1

0.000

MYD99, TNFRSF1A,
NFKBIA, RELA, RIPK1,
TLR4, NFKB1, FADD,
MAP3K7, TRAF6, IL1A,
TNF, CHUK, IKBKG,
MAP3K14

HSP27 PATHWAY

0.000

HSPB1, MAPKAPK2, FAS,
MAPKAPK3, ACTA1, IL1A

0.000

HSPB1, FAS, MAPKAPK2,
MAPKAPK3, ACTA1, IL1A,
TNF, BCL2

0.036

FOS, MAPK23, JUN,
MAPKAPK2, MAP3KA,
MAPK6, MAP3K6,
NFKBIA, RPS6KA1,
MAPKAPK3, MAPK11,
RELA, MAP4K5, MAP4K4,
TGFB3, RIPK1, NFKB1,
STAT1, MAP2K7, SP1,
MAPK12, RPS6KB1,
MEF2C, MAP3K7,
RPS6KA3, TGFBR1,
RPS6KB2, SHC1, CHUK,
CREB1, MYC

0.000

HSPB1, MAPKAPK2,
DDIT3, HMGN1, TGFB3,
RIPK1, CDC42, STAT1,
MEF2C, MAP3K7,
TGFBR1, SHC1, CREB1,
MYC, ATF2, HSPB2

CELL SURVIVAL

MAPK PATHWAY

P38 MAPK PATHWAY

0.000

0.031

FOS, JUN, MAP2K3,
MAPKAPK2, MAPKAPK3,
SHC1, PRS6KA1, STAT1,
MAP3K8, RELA, MAPK6,
MAPK9, MAX, MAP3K6,
MAP3K14, NFKB1, RIPK1,
NFKBIA, TRAF2, MAPK4,
MAPK12, MAPK7

CDKN1A, GADD45A,
CDK2, IMP3, CCND1,
PCNA, BAX
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APPENDIX 1, Continued
WT P
Value

WT Genes (with Core
Enrichment)

GSK3 PATHWAY

0.000

CD14, LBP, MYD88,
CCND1, RELA, FZD1,
TIRAP, NFKB1, LY96,
CTNNB1, TLR4

0.000

SODD PATHWAY

0.000

TNFRSF1A, FADD,
CASP9, RIPK1, TRAF2

0.038

TNFR1 PATHWAY

0.036

Not reported by GSEA

0.000

0.000

HSPB1, TUBA6, GREB1

0.000

HSPB1, GREB1, TUBA6

NTHI PATHWAY

0.017

TLR2, DUSP1, MAP2K3,
MYD88, TGFBR2, RELA,
IL1B, MAP3K14, NFKB1,
NFKBIA

0.019

TLR2, MAP2K3, MYD88,
DUSP1, NFKBIA,
TGFBR2, IL1B, MAPK11,
RELA, NFKB1, MAP3K7,
TNF, TGFBR1, CHUK

RNA PATHWAY

0.017

DNAJC3, RELA, EIF2S2,
MAP3K14, NFKB1, NFKBIA

0.000

NFKBIA, RELA, NFKB1,
DNAJC3, CHUK, IF2S2,
MAP3K14, EIF2S1

RANKL PATHWAY

0.019

FOS, RELA, NFKB1,
IFNAR2, TRAF6, TNFSF11,
TNFRSF11A

0.000

FOS, RELA, NFKB1,
TRAF6, TNFRSF11A

HIVNEF PATHWAY

0.036

ARHGDIB, LMNA,
TNFRSF1A, FADD,
LMNB1, CDC2L1, CASP8,
RELA, MAP3K14, NFKB1,
RIPK1, NFKBIA, GSN,
TRAF2, CASP9, MAP2K7,
LMNB2, BIRC4, CASP3,
TNF, MDM2, MAP3K1,
CASP7, CASP2, PTK2,
CASP6, APAF1, BIRC3

0.000

TNFRSF1A, LMNA,
ARHGDIB, LMNB1,
PRKCD, NFKBIA,
CDC2L1, RELA, CASP8,
RIPK1, NFKB1, MAP2K7,
MDM2, FADD, PTK2, TNF,
CRADD, BCL2, CHUK,
BAG4, LMNB2, MAP3K14,
GSN

GLEEVEC PATHWAY

0.019

FOS, JUN, STAT1,
STAT5A

0.000

Not reported by GSEA

Biocarta Pathway

KO P
Value

KO Genes (with Core
Enrichment)
CD14, MYD88, TIRAP,
RELA, TLR4, TOLLIP,
NFKB1, LEF1, CCND1,
CTNNB1, APC, PIK3CA,
LY96, DVL1
TNFRSF1A, CASP8,
RIPK1, FADD, TNF, BAG4
JUN, TNFRSF1A, LMNA,
ARHGDIB, LMNB1,
CASP8, RIPK1, FADD,
MAP3K7, TNF, CRADD,
BAG4, LMNB2

OTHER
MTA3 PATHWAY
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